Doses are closed inside each drug; sources differ, some several-fold; most FDA labels say pediatric safety is not established. This page does not choose a drug.
Check every dose: formulary, electrophysiologist. Do not dose from EHRA 2025 Table 18: wrong units.
PP ↑: slower sinus rate. →: no change. n/s, or an interval not listed: not stated in sources read; not the same as no change. Adult: largely adult data.
| Drug | Target | ECG Adult | Acts at | Use cases | Side effects Adult, stop | Proarrhythmia Adult |
|---|---|---|---|---|---|---|
| Class 0: HCN channel blocker. | ||||||
| If | PP ↑, PR ↑ at times, QTc → | Sinus node | JET | Phosphenes, bradycardia | Low | |
| Class I: sodium channel blockers. Can stop reentry or favor it. | ||||||
| Ia: Nav1.5 open; IKr | PP ↓ or →, PR ↑, QRS ↑, QT ↑ | Atrium, His-Purkinje, ventricle, accessory pathway | Stable VT, pre-excited AF, refractory SVT | Hypotension, lupus-like. Amiodarone: not together unless a pediatric cardiologist directs | Moderate | |
| Ib: Nav1.5 inactivated | PP →, PR →, QRS →, QT ↓ | Ventricle, depolarized tissue | VF, pulseless VT | Tremor, seizures. Not in WPW | Low | |
| Ib: peak and late Na | PP →, PR →, QRS →, QT ↓ | Purkinje, ventricle | LQT3 | Nausea, tremor | Low | |
| Ic: Nav1.5 open, inactivated; RyR2 | PP ↑ slight or →, PR ↑, QRS ↑, QT ↑ mostly from QRS (label), → (JCS) | His-Purkinje, ventricle; AV node, atrium less; accessory pathway | AVRT, WPW, fetal SVT, CPVT | Dizziness, heart failure. Arrest with structural disease; hospital start | Moderate | |
| Ic: as flecainide; mild β | PP ↑ or →, PR ↑, QRS ↑, QT unclear with wide QRS (label), → (JCS) | His-Purkinje, AV node, accessory pathway | AVRT, WPW, atrial tachycardia | Dizziness, metallic taste. Not with structural disease or asthma; hospital start | Moderate | |
| Class II: autonomic. | ||||||
| IIa: β1 | PP ↑, PR ↑ | Sinus, AV nodes | IV SVT control | Hypotension. No loading dose in children (one table); others differ | Low | |
| IIa: β1 | PP ↑, PR ↑ | Sinus, AV nodes | SVT | Fatigue, hypotension | Low | |
| IIa: β1 | PP ↑, PR ↑ | Sinus, AV nodes | SVT | Fatigue, hypotension | Low | |
| IIa: β1, β2; weak Na | PP ↑, PR ↑ | Sinus, AV nodes | LQTS, CPVT, infant SVT | Bradycardia, bronchospasm, hypoglycemia | Low | |
| IIa: β1, β2 | PP ↑, PR ↑ | Sinus, AV nodes | LQTS, CPVT, SVT | Fatigue, hypotension. Not in asthma | Low | |
| IId: vagal; Na-K ATPase | PP ↑, PR ↑, QT ↓ | Sinus, AV nodes, atrium | Infant and fetal SVT without WPW | Nausea, visual changes. Not with pre-excitation; narrow window | Moderate | |
| IIe: A1 agonist | PP ↑, PR ↑, QRS → | Sinus, AV nodes, atrium | Ends AV node-dependent SVT | Transient block, bronchoconstriction. Wide QRS only if regular, monomorphic | Moderate | |
| Class III: potassium channel blockers. Longer refractoriness, less reentry; torsades risk. | ||||||
| IIIa: K; Na, Ca, α, β | Oral: PP ↑, PR ↑, QRS →, QT ↑. IV: PR ↑, little else | All tissues oral; AV node first IV | VF, pulseless VT, refractory SVT, JET, PJRT | Hypotension IV; thyroid, liver, lung. Known long QT, shockable rhythm: avoid | Low | |
| IIIa: IKr; β1, β2 | PP ↑, PR ↑, QRS →, QT ↑ | Nodes, atrium, ventricle, accessory pathway | Flutter, IART, SVT, VT, fetal | Fatigue, hypotension. QTc over 450 ms or K under 4: contraindicated | High | |
| Class IV: calcium channel blockers. Slow the AV node. No change in muscle conduction or refractoriness; contractility falls, with hypotension. | ||||||
| IVa: ICa,L | PP ↑ or →, PR ↑, QRS → | Sinus, AV nodes | SVT over 1 year, fascicular VT | Myocardial depression, hypotension. IV: not in wide-complex VT, diagnosis first, or pre-excited AF/flutter; not under 1 year, under 2 years in one table | Low | |
| IVa: ICa,L | PP ↑, PR ↑, QRS → | Sinus, AV nodes | SVT, rate control | Myocardial depression, hypotension. Not in VT, diagnosis first, or pre-excited AF/flutter; not under 1 year, under 2 years in one table | Low | |
| Outside the classes | ||||||
| Ca2+ channel block (Lei 2018) | n/s | n/s | Torsades, JET prevention | Hypotension if fast. Heart block: contraindicated on some labels | n/s | |
Other classes (Id, IIb, IIc, IIIb, IIIc, IVb, V, VI, VII): no drug here. Scheme: EHRA 2025 Table 1, simplified from Lei 2018, which differs in places. Sources: method.
What sources describe, not a recommendation. Tap a use case for its detail, a drug for its panel.
| Use case | Mechanism | Drugs described, side effects |
|---|---|---|
| Reentry through the AV node | Acute: (transient AV block, bronchoconstriction, AF) (AHA/AAP 2025); Adult (hypotension, bradycardia), discouraged with known pre-excitation. Adult IV (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension); (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension), without pre-excitation (EHRA 2025); calcium channel blockers “should probably not be used in children” (Breinig 2026 R17). Refractory: (hypotension, lupus-like syndrome, torsades); (hypotension IV; thyroid, liver, lung): not together unless a pediatric cardiologist directs it (Korean 2025). Prevention: (bradycardia, bronchospasm, hypoglycemia), WPW: see its panel; (nausea, visual changes, AV block), not with WPW; Adult (not with structural disease; dizziness, heart failure); (not with structural disease; dizziness, heart failure) (EHRA 2025; AHA/AAP 2025; Breinig 2026) | |
| Reentry or AF over an accessory pathway | Adult (hypotension, lupus-like syndrome, torsades); (not with structural disease; dizziness, heart failure); (not with structural disease; dizziness, heart failure). Digoxin, verapamil and diltiazem are discouraged or contraindicated. β-blockers in pre-excited AF: contraindicated, III: Harm Adult (ACC/AHA 2023) guideline, and “not recommended”, III, level B Adult (ESC 2019) guideline. Known pre-excitation: discouraged Adult (EHRA 2025) consensus; acute orthodromic AVRT and prophylaxis: sources disagree. Propranolol labels: beta-adrenergic blockade in WPW with tachycardia “has been associated with severe bradycardia requiring treatment with a pacemaker” FDA label. IV amiodarone may precipitate VF. (transient AV block, bronchoconstriction, AF) may induce AF with a rapid ventricular response Adult (EHRA 2025); in irregular wide QRS it can lead to VF (AHA/AAP 2025). should not be used in Wolff-Parkinson-White FDA label (EHRA 2025; EHRA/AEPC 2013) | |
| PJRT | Reentry over a concealed decremental accessory pathway | Often refractory (Ciriello 2024) review. (hypotension IV; thyroid, liver, lung) with a β-blocker, benefit in all treated; (not with structural disease; dizziness, heart failure) or (not with structural disease; dizziness, heart failure) alone, over 70% (Srinivasan 2019, Kang series) review |
| Focal atrial tachycardia | Automaticity, triggered activity or micro-reentry (JCS/JHRS 2020) | Adult (transient AV block, bronchoconstriction, AF) for diagnosis; (hypotension, bradycardia); Adult IV (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension); (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension); then (not with structural disease; dizziness, heart failure); (not with structural disease; dizziness, heart failure); (hypotension IV; thyroid, liver, lung) (EHRA 2025) |
| Enhanced automaticity | (hypotension IV; thyroid, liver, lung); (hypotension, lupus-like syndrome, torsades): not together unless a pediatric cardiologist directs it (Korean 2025). (phosphenes, bradycardia); (hypotension if fast) for prevention (EHRA 2025; JCS/JHRS 2020; Mendel 2022) | |
| Macro-reentry | (torsades, bradycardia) (Geanacopoulos 2024) review; (hypotension IV; thyroid, liver, lung), whose atrial slowing makes 1:1 conduction more likely. Long-term drug management has been disappointing (EHRA/AEPC 2013) consensus. Adult Class Ic does not terminate flutter and risks 1:1 conduction (EHRA 2025) | |
| Not stated in sources read | Shock first. If shock-refractory: (hypotension IV; thyroid, liver, lung), known long QT: avoid (Singapore 2026) guideline; (tremor, seizures, hypotension) (AHA/AAP 2025) | |
| SVT with aberrancy is most common | Expert consultation first; no support for or against a specific drug (AHA/AAP 2025). (transient AV block, bronchoconstriction, AF) if regular, monomorphic; (hypotension, lupus-like syndrome, torsades) (EHRA/AEPC 2013 Table 2) consensus; (hypotension IV; thyroid, liver, lung): not together unless a pediatric cardiologist directs it (Korean 2025); (tremor, seizures, hypotension) (JCS/JHRS 2020). If irregular, may be pre-excited AF: IV amiodarone may precipitate VF Adult (EHRA 2025); lidocaine should not be used in WPW FDA label. IV verapamil, diltiazem contraindicated FDA label | |
| Reentry involving the left fascicles (EHRA/AEPC 2013) | (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension): over 1 year; contraindicated for neonates and infants (JCS/JHRS 2020 Table 72). Stable children over 12 months, expert consultation first (Escudero 2022) review. IV verapamil is contraindicated in wide-complex VT; proper diagnosis is imperative FDA label. EHRA 2025 consensus, an adult document, makes an exception for posterior fascicular VT even under 1 year: sources differ. | |
| cAMP-mediated triggered DADs | Adult (transient AV block, bronchoconstriction, AF); β-blockers; (not under 1 year, one table under 2; diagnosis first in wide QRS; myocardial depression, hypotension); (torsades, bradycardia) (EHRA 2025; Escudero 2022, review) | |
| EAD-triggered | (Singapore 2026), rapidly; rapid administration may cause hypotension (Korean 2025) | |
| Adrenergic triggers; EADs | Adult (fatigue, hypotension); (bradycardia, bronchospasm, hypoglycemia); (nausea, tremor) in LQT3 and some LQT2. β-blockers may be pro-arrhythmic in LQT3 (EHRA/AEPC 2013) consensus. Avoid amiodarone in a shockable rhythm (EHRA 2025; Singapore 2026) | |
| DADs from RyR2 calcium release | Adult (fatigue, hypotension); (bradycardia, bronchospasm, hypoglycemia) (EHRA 2025); (not with structural disease; dizziness, heart failure) added if syncope or VT persists on β-blockers, IIa, C; alone if not tolerated, IIb, C (JCS/JHRS 2020). β-blockers and/or flecainide (Escudero 2022) review | |
| ARVC | Reentry around scar; adipocyte infiltration (JCS/JHRS 2020) | Adult β-blockers first; (not with structural disease; dizziness, heart failure); (torsades, bradycardia); (hypotension IV; thyroid, liver, lung): small studies, long-term effect minimal or not established. ARVC is structural disease; the FDA label and EHRA/AEPC 2013 warn against class Ic in children with it: these conflict. (EHRA 2025) |
| Brugada drug testing | Sodium channel block unmasks the type 1 pattern | Adult Ajmaline or (not with structural disease; dizziness, heart failure); (hypotension, lupus-like syndrome, torsades) less likely to provoke it. Sodium channel blockers are avoided in treatment (EHRA 2025) |
| Fetal tachyarrhythmia | Not stated. Share of fetal tachyarrhythmias: SVT 73.2%, flutter 26.2% (a review, as cited in Breinig 2026) | (nausea, visual changes, AV block); (not with structural disease; dizziness, heart failure), more effective than digoxin for SVT; (torsades, bradycardia). Effects in mother and fetus (EHRA 2025, Foetal arrhythmias) |
| Reentry | (bradycardia, bronchospasm, hypoglycemia), WPW: see its panel; (nausea, visual changes, AV block), not with WPW; (not with structural disease; dizziness, heart failure); (not with structural disease; dizziness, heart failure); (torsades, bradycardia) (Ciriello 2024, review; Sanatani 2012, abstract; Wei 2022, registry and review) | |
| Not an arrhythmia mechanism | Sodium channel blocker, β-blocker, calcium channel blocker, digoxin, torsades (Geanacopoulos 2024, review; Oeffl 2023, review) |
Lower pacemaker drive or phase 4 slope: Class 0, Ib, Ic, II, IV (EHRA 2025)
Wavelength = refractory period × conduction velocity (Rensma 1988, dogs). A positive excitable gap (circuit minus wavelength) sustains it. Class I can block the injured region; Class III narrows the gap; Class II, IV: AV node circuits (JCS/JHRS 2020; EHRA 2025)
EADs and DADs: Class I, II, IV; RyR2 block in CPVT; Class Ia, III can cause EADs (EHRA 2025)
Ivabradine; Class II, IV; sotalol, amiodarone
Class Ia, III lengthen refractoriness. Class Ic slows conduction. Digoxin, adenosine shorten refractoriness, which promotes re-entry; unlikely to end AF or flutter
Class II, IV; sotalol, amiodarone, propafenone
Class Ic most; procainamide; mexiletine
Class I, III. Class IV: no change in muscle conduction or refractoriness. Contractility falls most with Class Ic, IV
Class Ic, procainamide, sotalol. Known pre-excitation: AV nodal blockers favor conduction over the pathway if AF occurs: discouraged; digoxin contraindicated Adult (EHRA 2025)
(EHRA 2025; FDA labels)
Stop: Wide QRS only if regular and monomorphic. Asthma, second- or third-degree AV block: see warnings.
Class IIe: A1 receptor activator (EHRA 2025 Table 1). Activates IK,ACh, inhibits If, indirectly lowers ICa,L; abolishes catecholamine-induced EADs and DADs (EHRA 2025).
Sinus rate slows, PR lengthens, then transient AV block ends AV node-dependent tachycardia. Atrial refractoriness shortens. No effect on His-Purkinje or normal accessory pathway conduction; decremental pathways may block (EHRA 2025). QT: not stated in sources read.
SVT after vagal maneuvers fail: AVNRT, AVRT, triggered focal atrial tachycardia; transient block unmasks flutter. Unlikely to end AF, flutter or macro-reentry outside the AV node. Can end RVOT VT from triggered DADs, less often left fascicular VT (EHRA 2025).
Sinoatrial and AV block, bronchoconstriction, hypotension, seizures, AF; fatal cardiac events reported FDA label. Proarrhythmia moderate: transient bradycardia and AV block, AF, PACs, PVCs Adult (EHRA 2025 Table 10).
Wide QRS: only if regular and monomorphic; irregular may be pre-excited AF, and adenosine can lead to VF (AHA/AAP 2025)
Contraindicated: second- or third-degree AV block or sinus node disease without a pacemaker FDA label. Asthma or bronchospastic lung disease: contraindicated on some labels FDA label and (EHRA/AEPC 2013); avoid in severe asthma or active wheeze (Ciriello 2024). May induce AF with a rapid ventricular response with an accessory pathway, even when previously unknown Adult (EHRA 2025). Transplanted hearts are hypersensitive: consider a lower dose (Geanacopoulos 2024)
Running rhythm strip or multilead ECG (AHA/AAP 2025). Continuous ECG, blood pressure, respiration (Ciriello 2024); atropine at hand (Breinig 2026)
Adult Dipyridamole potentiates: reduce dose. Theophylline and caffeine antagonize: increase dose (EHRA 2025 Table 15)
0.1 mg/kg rapid push (max 6 mg), then consider 0.2 mg/kg (max 12 mg), class I, C-LD (AHA/AAP 2025 Figure 7; Korean 2025; Breinig 2026) guideline
Adds a third step, 0.3 mg/kg (max 18 mg) (Singapore 2026) guideline; the FDA label says over 12 mg is not recommended: these differ
Under 50 kg: 0.05–0.1 mg/kg; after 1–2 min raise by 0.05–0.1 mg/kg, to max single dose 0.3 mg/kg. 50 kg and over: adult dose FDA label
Rapid bolus and flush, as close to the heart as possible; lower-limb veins or PICC lines may fail (Ciriello 2024)
Infants 0.15 mg/kg; over 1 year 0.1 mg/kg; up to 0.3 mg/kg, class I, B; lower starting doses terminated too few (EHRA/AEPC 2013 Table 1) consensus
Infants 0.10–0.15 mg/kg (Ciriello 2024) review. Double first dose may be considered in infants (Breinig 2026) guideline
Adult 6, 12 and 18 mg boluses (EHRA 2025 Table 2). 6 mg, then 12 mg, may repeat 12 mg; over 12 mg not recommended FDA label
Stop: Severe bradycardia, heart block, shock, decompensated heart failure: contraindicated. Not with IV verapamil or diltiazem. Pre-excited AF: contraindicated Adult. Wide QRS: exclude antidromic first.
Class IIa: β1-blocker (EHRA 2025 Table 1). Onset 1–2 min, duration about 10 min (EHRA 2025). Reduce β-adrenoceptor-dependent phosphorylation of ion channels and calcium-handling proteins: fewer EADs and DADs, less automaticity, slower AV conduction (EHRA 2025).
Heart rate falls, sinus cycle length and sinus node recovery time rise, AH lengthens FDA label. QRS and QT: not stated in sources read.
IV to end supraventricular arrhythmias (EHRA 2025). Stable regular SVT of uncertain type Adult (EHRA 2025). IV control of SVT in PICU, usable at LVEF 25–50% (Breinig 2026 Table 2). Bidirectional VT (Escudero 2022).
Hypotension: asymptomatic 25%, symptomatic 12%; infusion site reactions 8% Adult FDA label. Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
No loading dose in children (Breinig 2026 Table 2) guideline table, ungraded. Other sources below give boluses: these conflict.
Contraindicated: severe sinus bradycardia, heart block above first degree, sick sinus, decompensated heart failure, cardiogenic shock, pulmonary hypertension; IV verapamil (fatal arrests) or IV diltiazem within a few hours FDA label. Also sinus bradycardia, conduction disorder, asthma; can be used at LVEF 25–50% (Breinig 2026 Table 2). Bradycardia, hypotension (Geanacopoulos 2024).
In pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020).
Antidromic AVRT, wide QRS: IV β-blocker “should be avoided” Adult (JCS/JHRS 2020). Stable wide QRS: esmolol with magnesium, “provided that antidromic conduction through an accessory AV pathway has been excluded” (EHRA/AEPC 2013 p 1352) consensus
Acute orthodromic AVRT only, manifest or concealed pathway: IV esmolol IIa, level C if vagal maneuvers and adenosine fail, without decompensated heart failure (ESC 2019); discouraged with known pre-excitation (EHRA 2025) consensus: these differ Adult. No pediatric source read explicitly permits IV use with pre-excitation.
Titrate to heart rate and blood pressure (Geanacopoulos 2024)
Raises lidocaine Adult (EHRA 2025 Table 15)
Continuous infusion: start 10–50 mcg/kg/min; raise by 25 mcg/kg/min every 10 min if needed; max 500 mcg/kg/min (Breinig 2026 Table 2) guideline table, ungraded
Reviews in infants stop at 200 mcg/kg/min (below). Adult FDA label: over 200 mcg/kg/min not recommended for tachycardia; safety above 300 not studied FDA label. Adult table max 300 mcg/kg/min, conversion ours: these differ.
FDA label: pediatric safety not established; no dose.
Conflicts with the no-load line above: bolus 500 mcg/kg, wide QRS of unknown mechanism, class IIb (EHRA/AEPC 2013 Table 2) consensus. Bolus 100–500 mcg/kg, then 25–100 mcg/kg/min (EHRA 2025 Table 18, not in the 2013 statement it cites) consensus
Bolus 100–500 mcg/kg over 1–2 min, then 100–500 mcg/kg/min (Geanacopoulos 2024) review
Infants 0.5 mg/kg (500 mcg/kg) rapid bolus, then 50–200 mcg/kg/min (Ciriello 2024; Srinivasan 2019) review
Well documented up to 48 h, then move to another β-blocker (Oeffl 2023) review
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Acute: ESC 2019 p 690, table for AVRT “due to manifest or concealed accessory pathways”. EHRA 2025, PSVT, intravenous, for the risk if AF occurs. JCS/JHRS 2020 Table 15, footnote.
Practice, not advice: a survey of North American pediatric cardiologists, published 2006, 295 of 1534 with complete data, infants with pre-excitation: acute, esmolol 17% (Wong 2006, abstract; reported in Srinivasan 2019) review.
Adult 0.5 mg/kg in 1 min; 0.05–0.2 mg/kg/min (max 0.3 mg/kg/min) (EHRA 2025 Table 2)
Stop: Shock, sinus bradycardia, block above first degree, asthma: contraindicated. Pre-excited AF: contraindicated Adult; prophylaxis with pre-excitation: sources disagree. Injection not recommended for pediatric arrhythmias.
Class IIa: β1- and β2-blocker (EHRA 2025 Table 1); higher affinity for sodium channels than other β-blockers (EHRA 2025). Reduce β-adrenoceptor-dependent phosphorylation of ion channels and calcium-handling proteins: fewer EADs and DADs, less automaticity, slower AV conduction (EHRA 2025).
Sinus rate slows, PR lengthens; LV function falls (JCS/JHRS 2020 Table 6). QRS and QT: not stated in sources read.
Non-selective β-blockers appear more effective than β1-selective ones in LQTS and CPVT Adult (EHRA 2025). LQTS types 1 and 2, CPVT Adult (EHRA 2025 Tables 3, 4). Infant SVT prophylaxis (Ciriello 2024; Sanatani 2012).
Fatigue, dizziness, hypotension, cold extremities; bronchospasm 1–5% Adult (EHRA 2025 Table 12). Crosses the blood-brain barrier: more CNS effects than nadolol (EHRA 2025). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated: cardiogenic shock, sinus bradycardia, heart block above first degree, asthma FDA label. Also AV block, conduction disorder (Breinig 2026 Table 2). IV verapamil or IV diltiazem within a few hours: contraindicated FDA label
In pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020).
Antidromic AVRT, wide QRS: IV β-blocker “should be avoided” Adult (JCS/JHRS 2020).
Acute orthodromic AVRT only: IV esmolol or metoprolol IIa, level C (ESC 2019); discouraged with known pre-excitation (EHRA 2025): these differ Adult: . Injection: not recommended for pediatric arrhythmias FDA label; no pediatric source read explicitly permits it with pre-excitation.
Prophylaxis of SVT with pre-excitation: sources disagree. For: β-blocker IIb, level C under 15 kg, not listed for recurrent SVT from 15 kg (JCS/JHRS 2020 Table 70); typical first line under 20 kg (ACC.org 2025) expert analysis. Against: “contraindicated” (EHRA/AEPC 2013) consensus; discouraged Adult (EHRA 2025) consensus; β-blocker only without pre-excitation on ECG: I, level A, caution even if intermittent Adult (JCS/JHRS 2020); IIa, level B Adult (ESC 2019).
Beta-adrenergic blockade in WPW with tachycardia “has been associated with severe bradycardia requiring treatment with a pacemaker” FDA label
Hypoglycemia, poor feeding (Ciriello 2024). Bronchospasm and heart failure reported in children FDA label. Do not stop abruptly: taper Adult FDA label
Heart rate, blood pressure, glucose (Ciriello 2024)
Raises procainamide and lidocaine Adult (EHRA 2025 Table 15)
1–3 mg/kg/day in 3–4 doses (JCS/JHRS 2020 Table 78) guideline
Start 1–3 mg/kg/day in 3 doses; every 3–5 days as needed and tolerated, to max 8–16 mg/kg/day in 3 doses, max 320 mg/day (Breinig 2026 Table 2) guideline table, ungraded. That ceiling is well above the other sources below, which stop at 3–6 mg/kg/day, and the adult table’s 240 mg/day: these differ.
Oral FDA label: not established; no dose.
0.05–0.1 mg/kg over 10 min (JCS/JHRS 2020 Table 78) guideline
FDA injection label: not recommended for cardiac arrhythmias in pediatric patients.
Oral 1–3 mg/kg/day in 3 doses (EHRA/AEPC 2013 Table 3) consensus. 1–6 mg/kg/day every 6–8 h (Leoni 2023) society review
Oral 1–5 mg/kg/day in 3 doses, start 1–2 (Ciriello 2024); 2–4 mg/kg/day in 3–4 doses (Geanacopoulos 2024); neonates 2–5 mg/kg/day every 6–8 h (Srinivasan 2019) review
IV 0.025–0.2 mg/kg in 10 min (Leoni 2023) society review. 0.1 mg/kg slowly (Ciriello 2024) review
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Acute: ESC 2019 p 690, table for AVRT “due to manifest or concealed accessory pathways”. EHRA 2025, PSVT, intravenous, for the risk if AF occurs. JCS/JHRS 2020 Table 15, footnote.
Acute, in full: if vagal maneuvers and adenosine fail, without decompensated heart failure; manifest or concealed pathway (ESC 2019). Injection label: short-term, to decrease ventricular rate, for SVT “including Wolff-Parkinson-White syndrome” Adult FDA label. Leoni 2023 Table 1 lists IV propranolol for children’s PSVT, and verapamil, with no pre-excitation condition society review.
Prophylaxis: EHRA/AEPC 2013 p 1355, in its text, no class. EHRA 2025, AVRT prevention, for the risk if AF occurs.
JCS/JHRS 2020 Table 70, WPW: recurrent or symptomatic SVT under 15 kg, β-blocker IIb, level C. At 15 kg or more: β-blocker IIb, level C after aborted sudden death, syncope or decreased cardiac function; no β-blocker row for recurrent persistent SVT induced on electrophysiology study, or palpitations. Same table, under 15 kg: class Ic I; sotalol or class IA IIa; amiodarone or ablation IIb; all level C. In children with pre-excitation syndrome, class IC, IA or III drugs “are preferred” (JCS/JHRS 2020 11.1.4.2) guideline. Leoni 2023, ages 0–12, prophylaxis for WPW and PSVT together, pre-excitation not specified: “Class IC drugs and amiodarone can also be used in combination with beta blockers” society review. JCS/JHRS 2020 Table 16, “in patients without manifest (including intermittent) WPW syndrome”, and 4.3 Adult. ESC 2019 p 690, “if no signs of pre-excitation are present on resting ECG” Adult.
Practice, not advice: a survey of North American pediatric cardiologists, published 2006, 295 of 1534 with complete data, infants with pre-excitation: acute, propranolol 34%, esmolol 17%; chronic, propranolol 70%, atenolol 6% (Wong 2006, abstract; reported in Srinivasan 2019) review.
Adult IV 1–3 mg in 1 min, repeat every 2–5 min up to 5 mg (max 0.2 mg/kg). Oral 20–40 mg IR/6 h or 80–160 mg ER/day (max 240 mg/day) (EHRA 2025 Table 2)
Stop: Bradycardia, heart block, shock, overt heart failure: contraindicated. Pre-excited AF: contraindicated Adult; prophylaxis with pre-excitation: sources disagree.
Class IIa: β1-blocker (EHRA 2025 Table 1). Reduce β-adrenoceptor-dependent phosphorylation of ion channels and calcium-handling proteins: fewer EADs and DADs, less automaticity, slower AV conduction (EHRA 2025).
Sinus cycle length and sinus node recovery time rise; AV node conduction prolonged FDA label. QRS and QT: not stated in sources read.
SVT (Breinig 2026 Table 2). AF or flutter rate control, idiopathic VT and PVCs Adult (EHRA 2025 Table 4). Non-selective β-blockers appear more effective than β1-selective ones in LQTS and CPVT Adult (EHRA 2025).
Fatigue, dizziness, hypotension, cold extremities; bronchospasm 1–5% Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated: sinus bradycardia, heart block above first degree, cardiogenic shock, overt cardiac failure FDA label. Also conduction disorder, asthma (Breinig 2026 Table 2). Do not stop abruptly: taper Adult FDA label. Adult IV dose below: IV verapamil or IV diltiazem within a few hours contraindicated FDA label
In pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020).
Prophylaxis of SVT with pre-excitation: sources disagree in class terms, for recurrent SVT under 15–20 kg; no source read advises atenolol by name for prophylaxis. Against: “contraindicated” (EHRA/AEPC 2013) consensus; discouraged Adult (EHRA 2025) consensus. Both sides: .
Heart rate, blood pressure, glucose (Ciriello 2024, β-blockers)
Half-life 16 h in newborns, up to 7 h from age 5 (Oeffl 2023)
1–2 mg/kg once daily (JCS/JHRS 2020 Table 78) guideline
Start 0.5–1 mg/kg/day in 1–2 doses; to max 2 mg/kg/day in 2 doses, max 100 mg/day (Breinig 2026 Table 2) guideline table, ungraded
FDA label: not established; no dose.
0.3–1.3 mg/kg/day once daily (EHRA/AEPC 2013 Table 3) consensus (Ciriello 2024) review. 0.3–1.0 mg/kg/day, every 12 or 24 h; max 2 mg/kg/day or 100 mg/day (Oeffl 2023 Table 3) review
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Prophylaxis: EHRA/AEPC 2013 p 1355, in its text, no class. EHRA 2025, AVRT prevention, for the risk if AF occurs.
Leoni 2023 Table 1 lists no atenolol.
Practice, not advice: a survey of North American pediatric cardiologists, published 2006, 295 of 1534 with complete data, infants with pre-excitation: chronic, atenolol 6% (Wong 2006, abstract; reported in Srinivasan 2019) review.
Adult Oral 25–50 mg/day (max 100 mg/day). IV 2.5 mg in 2.5 min, repeated at 5-min intervals (max 10 mg) (EHRA 2025 Table 2)
Stop: Severe bradycardia, heart block, shock, decompensated heart failure: contraindicated. Pre-excited AF: contraindicated Adult; prophylaxis with pre-excitation: sources disagree.
Class IIa: β1-blocker (EHRA 2025 Table 1). Reduce β-adrenoceptor-dependent phosphorylation of ion channels and calcium-handling proteins: fewer EADs and DADs, less automaticity, slower AV conduction (EHRA 2025).
Sinus rate slows, AV nodal conduction falls FDA label. QRS and QT: not stated in sources read.
SVT (Leoni 2023; Oeffl 2023). AF or flutter rate control, idiopathic VT and PVCs Adult (EHRA 2025 Table 4). Non-selective β-blockers appear more effective than β1-selective ones in LQTS and CPVT Adult (EHRA 2025).
Fatigue, dizziness, hypotension, cold extremities; bronchospasm 1–5% Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated: severe bradycardia, second- or third-degree heart block, sick sinus without a pacemaker, cardiogenic shock, decompensated heart failure; systolic under 100 mm Hg Adult FDA label. Do not stop abruptly: taper Adult FDA label. Adult IV dose below: IV verapamil or IV diltiazem within a few hours contraindicated; injection label adds heart rate under 45, PR 0.24 s or more Adult FDA label
In pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020).
Antidromic AVRT, wide QRS: IV β-blocker “should be avoided” Adult (JCS/JHRS 2020).
Acute orthodromic AVRT only, manifest or concealed pathway: IV metoprolol IIa, level C if vagal maneuvers and adenosine fail, without decompensated heart failure (ESC 2019); discouraged with known pre-excitation (EHRA 2025) consensus: these differ Adult. No pediatric source read explicitly permits IV use with pre-excitation.
Prophylaxis of SVT with pre-excitation: sources disagree in class terms, for recurrent SVT under 15–20 kg; no source read advises metoprolol by name for prophylaxis. Against: “contraindicated” (EHRA/AEPC 2013) consensus; discouraged Adult (EHRA 2025) consensus. Both sides: .
Succinate tablets: bradycardia, heart block and cardiac arrest have occurred; patients with “conduction disorders (including Wolff-Parkinson-White)” “may be at increased risk” FDA label
Hypotension, bradycardia, fatigue; half-life depends on CYP2D6 (Oeffl 2023)
Heart rate, blood pressure, glucose (Ciriello 2024, β-blockers)
1–2 mg/kg/day every 12 h (Leoni 2023) society review. A wider literature range, 0.5–6 mg/kg/day every 8–12 h (Oeffl 2023 Table 3) review
No guideline or FDA label dose read.
Gap: only one review gives an IV dose, so none is shown.
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Acute: ESC 2019 p 690, table for AVRT “due to manifest or concealed accessory pathways”. EHRA 2025, PSVT, intravenous, for the risk if AF occurs. JCS/JHRS 2020 Table 15, footnote.
Prophylaxis: EHRA/AEPC 2013 p 1355, in its text, no class. EHRA 2025, AVRT prevention, for the risk if AF occurs.
Leoni 2023 Table 1, a WPW and accessory pathway review, lists it for children’s PSVT, oral, without a pre-excitation condition, as it does verapamil society review.
Adult IV 5 mg in 2 min (max 15 mg). Oral 25–100 mg/12 h tartrate, or 50–200 mg/day XL succinate (EHRA 2025 Table 2)
Stop: Asthma, bradycardia, block, shock, overt heart failure: contraindicated. Pre-excited AF: contraindicated Adult; prophylaxis with pre-excitation: sources disagree. Do not stop abruptly Adult
Class IIa: β1- and β2-blocker (EHRA 2025 Table 1); renally excreted (EHRA 2025). Reduce β-adrenoceptor-dependent phosphorylation of ion channels and calcium-handling proteins: fewer EADs and DADs, less automaticity, slower AV conduction (EHRA 2025).
Sinus rate slows, PR lengthens; LV function falls (JCS/JHRS 2020 Table 6). QRS and QT: not stated in sources read.
Non-selective β-blockers appear more effective than β1-selective ones in LQTS and CPVT Adult (EHRA 2025). Among the most used in channelopathies: LQTS types 1 and 2, CPVT Adult (EHRA 2025 Tables 3, 4). SVT (Breinig 2026 Table 2; Leoni 2023).
Fatigue, dizziness, hypotension, cold extremities; bronchospasm 1–5% Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated: asthma, sinus bradycardia, block above first degree, cardiogenic shock, overt cardiac failure FDA label. Also conduction disorder (Breinig 2026 Table 2). Do not stop abruptly: taper over 1–2 weeks Adult FDA label. Not available in every country (Oeffl 2023)
In pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020).
Prophylaxis of SVT with pre-excitation: sources disagree in class terms, for recurrent SVT under 15–20 kg; no source read advises nadolol by name for prophylaxis. Against: “contraindicated” (EHRA/AEPC 2013) consensus; discouraged Adult (EHRA 2025) consensus. Both sides: .
Heart rate, blood pressure, glucose (Ciriello 2024, β-blockers)
Start 0.5–1 mg/kg/day in 1–2 doses, max 40 mg/dose; every 3 days to max 2.5 mg/kg/day in 2 doses, max 320 mg/day (Breinig 2026 Table 2) guideline table, ungraded
FDA label: not established; no dose.
0.5–2 mg/kg/day every 12–24 h (Leoni 2023 Table 1) society review. Oeffl 2023 review prints its range and maximum inconsistently, so it is not shown.
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Prophylaxis: EHRA/AEPC 2013 p 1355, in its text, no class. EHRA 2025, AVRT prevention, for the risk if AF occurs.
Leoni 2023 Table 1, a WPW and accessory pathway review, lists it for children’s PSVT, oral, without a pre-excitation condition, as it does verapamil society review.
Adult Oral 40–80 mg/day (max 320 mg/day) (EHRA 2025 Table 2)
Stop: Cardiac arrest and sudden death with structural heart disease; start in hospital.
Class Ic: Nav1.5 open and inactivated state, slow dissociation; also RyR2, relevant in CPVT (EHRA 2025 Table 1). Blocks late sodium current (EHRA 2025). In reentry, sodium block can turn unidirectional block in an injured region into bidirectional block; too little block shortens the wavelength, widens the excitable gap and favors reentry (JCS/JHRS 2020).
PR and QRS lengthen (JCS/JHRS 2020 Table 6). QT widens about 8%, mostly from QRS FDA label; no change (JCS/JHRS 2020 Table 5): these differ. Conduction slows most in His-Purkinje, less in AV node and atrium; refractoriness changes only in the ventricle; sinus cycle length rises slightly FDA label. Accessory pathway: slower conduction, longer refractoriness, particularly retrograde; effects grow with rate (EHRA 2025).
SVT including WPW (EHRA/AEPC 2013; Oeffl 2023); AVRT; AVNRT resistant to β-blockers or calcium channel blockers Adult (EHRA 2025). Fetal SVT, more effective than digoxin (EHRA 2025, Foetal arrhythmias). CPVT: added if syncope or VT persists on β-blockers, IIa, C; alone if not tolerated, IIb, C (JCS/JHRS 2020). LQT3 add-on Adult (EHRA 2025); (EHRA/AEPC 2013). ARVC: small studies Adult (EHRA 2025); it is structural disease: see warnings. Unmasks Brugada on testing Adult (EHRA 2025).
Dizziness, blurred vision 15–50%; fatigue; nausea; dyspnea or heart failure 5% Adult (EHRA 2025 Table 12). Proarrhythmia moderate: flutter in AF, monomorphic VT with structural disease, bradycardia with sinus node or AV disease Adult (EHRA 2025 Table 10).
In pediatric patients with structural heart disease, flecainide has been associated with cardiac arrest and sudden death. Start in hospital with rhythm monitoring; any use directly supervised by a cardiologist skilled in pediatric arrhythmias FDA label. Class I drugs and sotalol: start in hospital (EHRA/AEPC 2013 p 1355) consensus. Should not be used in children with structural heart disease (EHRA/AEPC 2013) consensus. Not to be used in Brugada syndrome Adult (EHRA 2025 Table 4)
Contraindicated: second- or third-degree AV block or bifascicular block without a pacemaker; cardiogenic shock FDA label. Also AV block, renal failure, severe heart failure, ischemic heart disease, QRS over 120 ms, QTc over 500 ms, QRS widening over 25% (Breinig 2026 Table 2) guideline table, ungraded
Boxed, adults: excess mortality in CAST; not recommended in chronic AF; VT, VF and death reported in AF or flutter FDA label.
QRS over 25% above baseline: lower dose or stop (EHRA/AEPC 2013 Table 3; Ciriello 2024). Incessant tachycardia can start during initiation in pre-excitation (EHRA/AEPC 2013)
Renal, sources differ: contraindicated at creatinine clearance under 50 mL/min (Ciriello 2024); start lower at 35 mL/min/1.73 m² or less FDA label; discouraged or reduced at GFR under 35 mL/min Adult (EHRA 2025)
Milk may inhibit absorption in infants; consider a lower dose when milk is removed from the diet. Plasma levels can jump with small dose changes, and on higher doses can rise rapidly to far above therapeutic on the same dose FDA label
Trough level and ECG after at least 5 doses and after any dose change, and at each visit in the first year. Trough levels during major changes in dietary milk intake. Usual trough in children 200–500 ng/mL; up to 800 ng/mL may be required FDA label. PR and QRS guide dose, serum levels seldom of use (EHRA/AEPC 2013) consensus: this differs from the label.
Exercise test: consider for QRS widening Adult (EHRA 2025 Table 8)
Renal elimination: adjust dose (EHRA 2025, Children).
Amiodarone: reduce flecainide by 50% FDA label (also Srinivasan 2019); by 30% Adult (EHRA 2025 Table 15)
Fluoxetine, paroxetine raise flecainide: replace the SSRI, or reduce flecainide 30%, check levels and ECG Adult (EHRA 2025 Table 15)
Digoxin rises: reduce digoxin 25% (EHRA 2025 Table 15, flecainide row) or 50% or avoid (Table 15, digitalis row)
1–4 mg/kg/day in 2 doses, max 200 mg (JCS/JHRS 2020 Table 78) guideline
Start 1–3 mg/kg/day, maintain 3–6 mg/kg/day, in 3 doses (Breinig 2026 Table 2) guideline table, ungraded
Under 6 months about 50 mg/m²/day in 2–3 doses; over 6 months may rise to 100 mg/m²/day; max 200 mg/m²/day, not to be exceeded FDA label. JCS stops at 200 mg; the label’s figure passes that above about 1 m² (our arithmetic): these differ.
1–2 mg/kg over 10 min, max 150 mg (JCS/JHRS 2020 Table 78) guideline. No IV form on the FDA label read.
Oral 2–7 mg/kg/day in 2 doses (EHRA/AEPC 2013 Table 3) consensus (Ciriello 2024) review. 2–6 mg/kg/day every 8–12 h (Leoni 2023) society review
Start 1–3 mg/kg/day or 50–100 mg/m²/day; maintain 3–6 mg/kg/day or 100–150 mg/m²/day; in 3 doses (Geanacopoulos 2024) review. Neonates start 2 mg/kg/day every 12 h (Srinivasan 2019) review
Effective 100–200 mg/m²/day or 1–8 mg/kg/day; toxicity may occur above these (Perry 1992, world literature) review abstract
IV over 5 min: 1.5–2 mg/kg, class IIa, B (EHRA/AEPC 2013 Table 1) consensus; 1–2 mg/kg (Ciriello 2024) review. Over 10 min 1–2 mg/kg (Leoni 2023) society review
May not be safe with structural disease and flutter or ventricular arrhythmias (Perry 1992) abstract. It is nonetheless used in children with CHD (Geanacopoulos 2024) review: a description of practice, not safety evidence.
Flecainide for SVT, arrest or death 8.3% with underlying heart disease vs 0.3% without (p<0.001) (Fish 1991) abstract
CPVT, β-blockers and flecainide: 22 of 29 with suppression, 14 complete, 8 partial Adult (EHRA 2025)
Raise the risk of dosing errors (Geanacopoulos 2024)
Adult Oral 100 mg/12 h or 200 mg ER/day (max 300 mg/day); load 300 mg. IV 2 mg/kg in 10 min (EHRA 2025 Table 2). Sustained VT: max 400 mg/day, loading dose not recommended FDA label
Stop: Not with structural heart disease, heart failure, Brugada, conduction disease or bronchospasm.
Class Ic: Nav1.5 open and inactivated state, slow dissociation; also RyR2 (EHRA 2025 Table 1). Blocks ICa,L; mild β-blockade Adult at higher doses (EHRA 2025). Reentry: .
PR and QRS lengthen; AH and HV prolong; AV nodal refractoriness rises; little or no effect on sinus node or atrial refractoriness; accessory pathway slows both ways FDA label. Sinus rate falls (JCS/JHRS 2020 Table 6): these differ. Wide QRS makes QT hard to interpret; it may prolong QT FDA label; no change (JCS/JHRS 2020 Table 5).
AVRT, WPW; resistant AVNRT; focal atrial tachycardia Adult (EHRA 2025 and Table 4). Alternative to flecainide in CPVT Adult (EHRA 2025).
SVT, VT, atrial and multifocal atrial tachycardia (Oeffl 2023 Table 6). 0 of 5 IART episodes converted (Przybylski 2023)
Dizziness, blurred vision 10–30%; metallic taste; nausea; fatigue, dyspnea or heart failure 5% Adult (EHRA 2025 Table 12). Proarrhythmia moderate: flutter in AF, monomorphic VT with structural disease, bradycardia Adult (EHRA 2025 Table 10).
Contraindicated: heart failure, cardiogenic shock, conduction disorders without a pacemaker, Brugada syndrome, bradycardia, marked hypotension, bronchospasm, marked electrolyte imbalance FDA label. Also listed: QRS over 120 ms, QTc over 500 ms (Breinig 2026 Table 2) guideline table, ungraded
Class I drugs and sotalol: start in hospital (EHRA/AEPC 2013 p 1355) consensus. Life-threatening ventricular arrhythmias: “Initiate treatment in the hospital” FDA label
Label: pediatric safety not established. Boxed, adults: excess mortality with class Ic in CAST FDA label. Should not be used with structural heart disease (EHRA/AEPC 2013) consensus.
Reduced LVEF: contraindicated; conduction disease or renal impairment: caution; QRS over 25%: lower dose or stop (EHRA/AEPC 2013 Table 3). In 772 children, cardiac arrest or sudden death 0.6%; adverse cardiac events 4.8% with structural disease, 1.5% without (Janousek 1998) abstract
QRS and QTc (Ciriello 2024). No therapeutic drug monitoring; saturable metabolism, increase dosing carefully (Breinig 2026 Table 2)
Dose adjustment may be needed with hepatic disease; not with renal dysfunction Adult (EHRA 2025). Renal dose adjustment needed in children (EHRA 2025, Children): these differ.
Adult Digoxin rises: reduce digoxin 25% or 50% as for flecainide. Fluoxetine and paroxetine raise propafenone. CYP2D6 variation changes levels (EHRA 2025 Table 15 and text)
Start 6–10 mg/kg/day in 3 doses; every 2–4 days to max 20 mg/kg/day in 3 doses, max 900 mg/day (Breinig 2026 Table 2) guideline table, ungraded
No guideline or FDA label dose read. Consensus and reviews are below.
Oral 200–600 mg/m² or 10–15 mg/kg/day in 3 doses (EHRA/AEPC 2013 Table 3) consensus. Same (Leoni 2023) society review (Ciriello 2024) review
Oral, neonates start 7–10 mg/kg/day every 8 h, up to 18–20 mg/kg/day (Srinivasan 2019) review. 6–20 mg/kg/day; max 900 mg/day (Oeffl 2023 Table 2) review
IV load 2 mg/kg over 2 h, then 4–7 mcg/kg/min, class IIa, B (EHRA/AEPC 2013 Table 1) consensus
IV load 0.5 mg/kg in 10 min (Leoni 2023) society review. 1–2 mg/kg over 2 h (Ciriello 2024) review. Infusion up to 20 mcg/kg/min (Oeffl 2023) review. These differ. EHRA 2025 and Ciriello 2024 print this rate in mg/kg/min; do not use their unit.
JCS/JHRS 2020 words its dose without “per day”, so it is not shown; see method.
Adult Oral 150–300 mg IR/8 h or 225–425 mg ER/12 h (max 900 mg/day); load 600 mg. IV 2 mg/kg in 10 min (EHRA 2025 Table 2)
Stop: Not with complete heart block, lupus, torsades; not with amiodarone unless a pediatric cardiologist directs.
Class Ia: Nav1.5 open state, intermediate dissociation; mild anti-cholinergic (EHRA 2025 Table 1). Also blocks IKr: less excitability, longer refractoriness (EHRA 2025). Affects conduction and refractoriness both, so can be anti- or proarrhythmic (JCS/JHRS 2020).
QRS widens; QT and PR lengthen less regularly; slight sinus tachycardia. Refractoriness rises in atria, less in His-Purkinje and ventricle; conduction slows in atria, His-Purkinje, ventricle; AV node variable FDA label. PR, QRS, JT lengthen, sinus rate unchanged (JCS/JHRS 2020 Table 6).
Stable monomorphic VT; pre-excited AF, slowing the accessory pathway Adult (EHRA 2025, Tables 3, 4). Brugada drug testing, less sensitive than ajmaline Adult (EHRA 2025).
Refractory or recurrent SVT in PICU (Breinig 2026 R17). Monomorphic VT; post-operative JET, particularly with hypothermia (Geanacopoulos 2024). Stable pre-excited AF (Escudero 2022)
Lupus-like syndrome 20–30%; hypotension 5%; nausea; blood dyscrasias 1% Adult (EHRA 2025 Table 12). Proarrhythmia moderate: AV block, monomorphic VT with structural disease, torsades Adult (EHRA 2025 Table 10). NAPA over 20 mcg/mL: torsades risk; procainamide over 10 mcg/mL: marked QRS widening Adult (EHRA 2025).
Contraindicated: complete heart block; second-degree block or hemiblock without a pacemaker; systemic lupus; torsades FDA label. Also long QTc over 500 ms, AV block and repolarization disorder, sinus bradycardia, QRS over 120 ms (Breinig 2026 Table 2). Avoid giving with amiodarone unless a pediatric cardiologist directs it (Korean 2025) guideline
Boxed: positive ANA and lupus-like syndrome with prolonged use; blood dyscrasias, some fatal, mostly in the first 12 weeks, so weekly blood counts for 3 months FDA label. Boxed, adults: CAST, excess mortality with encainide or flecainide; applicability uncertain; label reserves use for life-threatening ventricular arrhythmia FDA label
Torsades-related syncope in up to 20% of children with class IA (EHRA/AEPC 2013) consensus. Hypotension from vasodilation; toxicity mostly with hepatic or renal dysfunction: adjust and check levels (Geanacopoulos 2024; Srinivasan 2019)
Give the load slowly FDA label: hypotension from vasodilation (Geanacopoulos 2024). Blood pressure; procainamide and NAPA level 4 h after start, then daily; daily ECG (Geanacopoulos 2024)
Half hepatic, half renal; NAPA renally excreted: adjust in renal failure (EHRA 2025).
Adult Cimetidine, propranolol and verapamil raise it; amiodarone adds to it (EHRA 2025 Table 15)
10–15 mg/kg, max 500 mg/dose or total 1000 mg, over 30–60 min, then 20–80 mcg/kg/min, max 4000 mg/24 h (Breinig 2026 Table 2) guideline table, ungraded. 15 mg/kg reaches 500 mg at about 33 kg (our arithmetic). Its rationale prints max 1000 mg alone.
A review prints max 2 g/day, the adult table 1 g/day, and lower neonatal loads and rate (below): these differ. At 80 mcg/kg/min, 2 g/day is reached at about 17 kg and 4000 mg/24 h at about 35 kg; the adult table’s own 2–6 mg/min passes 1 g in 2.8–8.3 h (our arithmetic).
2–10 mg/kg over 10 min (JCS/JHRS 2020 Table 78) guideline. These differ in dose and rate.
FDA label: not established; no dose.
Neonates 7–10 mg/kg; children 10–15 mg/kg (max 1000–1500 mg) over 30–45 min; then 20–80 mcg/kg/min (max 2 g/day) (Geanacopoulos 2024) review. Neonates 7–15 mg/kg over 15–30 min, then 20–60 mcg/kg/min (Srinivasan 2019) review
Post-operative JET: load 3 mg/kg over 20 min or 10 mg/kg; infusion 40–120 mcg/kg/min (Mandapati 2000, n = 17) abstract
Wide QRS of unknown mechanism: class IIb, no dose given (EHRA/AEPC 2013 Table 2) consensus
Adult IV 100 mg, repeat every 5 min (max 500–750 mg, 50 mg/min); 2–6 mg/min (max 1 g/day) (EHRA 2025 Table 2)
Stop: Not in Wolff-Parkinson-White, Stokes-Adams or severe block.
Class Ib: Nav1.5 inactivated state, rapid dissociation (EHRA 2025 Table 1). Stronger in depolarized tissue and at fast rates, weaker with low potassium; no relevant potassium channel effect; lowers phase 4 slope and excitability (EHRA 2025).
PR and QRS unchanged, QT shortens (JCS/JHRS 2020 Table 5); JT shortens, sinus rate and LV function unchanged (JCS/JHRS 2020 Table 6). APD unaffected or shortened (EHRA 2025).
VF or pulseless VT, class IIb, C-LD (AHA/AAP 2025). Wide QRS (EHRA/AEPC 2013; JCS/JHRS 2020; Escudero 2022).
Dizziness, tremor, tinnitus 1–10%; hypotension; nausea; rash Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated or should not be used, by label: Wolff-Parkinson-White, Stokes-Adams, severe sinoatrial, AV or intraventricular block (severe block, most labels: without a pacemaker); amide anesthetic hypersensitivity FDA label
Tremor and seizures usually come before cardiorespiratory effects; caution with abnormal AV or intraventricular conduction; levels rise with hepatic impairment or low cardiac output (Geanacopoulos 2024). Lower the infusion in hepatic or severe renal impairment FDA label
ECG, blood pressure; level 1.5–5.0 mcg/mL if prolonged or metabolism altered (Geanacopoulos 2024)
Hepatic, CYP3A4; steady state much later with hepatic dysfunction, heart failure or shock; β-blockers impair metabolism (EHRA 2025).
Amiodarone and β-blockers raise it; phenobarbital lowers it (Geanacopoulos 2024; EHRA 2025 Table 15)
Arrest: 1 mg/kg, class IIb, C-LD (AHA/AAP 2025 Figure 2; Korean 2025) guideline
1 mg/kg (max 100 mg), then 20–50 mcg/kg/min; repeat the bolus if the infusion starts more than 15 min later (Singapore 2026) guideline
1 mg/kg, then 25–50 mcg/kg/min (printed as 0.025–0.05 mg/kg/min; conversion ours) (JCS/JHRS 2020 Table 78) guideline
1 mg/kg, then 20–50 mcg/kg/min; pediatric schedules were not studied FDA label
Wide QRS: 1 mg/kg, up to 3 doses at 10-min intervals, then 20–50 mcg/kg/min, class IIa, C (EHRA/AEPC 2013 Table 2) consensus. Same doses (Geanacopoulos 2024; Oeffl 2023) review
Adult 100 mg (1–1.5 mg/kg), may repeat 50 mg (0.5–0.75 mg/kg) in 5–10 min (max 3 mg/kg); 1–4 mg/min (EHRA 2025 Table 2)
Stop: Not in cardiogenic shock or second- or third-degree AV block without a pacemaker.
Class Ib: Nav1.5 inactivated state, rapid dissociation; secondary potassium channel block and α-blockade (EHRA 2025 Table 1). Inhibits peak and late sodium current (EHRA 2025).
Does not prolong QRS or QT FDA label. Shortens APD and refractoriness in Purkinje, less in ventricle; no change in sinus rate, contractility or AV node (EHRA 2025). JT shortens (JCS/JHRS 2020 Table 6).
LQT3 and some LQT2, added to β-blockers, only if a test dose shortens QTc by 40 ms or more Adult (EHRA 2025, Channelopathies). Sustained VT Adult (EHRA 2025).
Long QT type 3 (EHRA/AEPC 2013; Oeffl 2023). Ventricular tachyarrhythmias (JCS/JHRS 2020 Table 78)
Nausea, vomiting 5–40%; dizziness, ataxia, tremor 5–20%; hypotension, fatigue Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
Contraindicated: cardiogenic shock; second- or third-degree AV block without a pacemaker FDA label. Boxed, adults: CAST, excess mortality with encainide or flecainide; applicability uncertain; label reserves use for life-threatening ventricular arrhythmia; abnormal liver tests reported FDA label
Class I drugs and sotalol: start in hospital (EHRA/AEPC 2013 pp 1355, 1358) consensus. Starting it for life-threatening arrhythmias “should be carried out in the hospital” FDA label
Adult Gastrointestinal 5–40%, central nervous system 5–20% (EHRA 2025 Table 12). Class IB is rarely used in children (EHRA/AEPC 2013)
Adult Raises theophylline; phenytoin and mexiletine lower each other (EHRA 2025 Table 15)
5–15 mg/kg/day in 3–4 doses, max 450 mg/day (JCS/JHRS 2020 Table 78) guideline
FDA label: not established; no dose.
2–3 mg/kg over 5–10 min, then 0.4–0.6 mg/kg/h (JCS/JHRS 2020 Table 78) guideline. No IV form per EHRA 2025 Table 2.
Oral 1.4–5.0 mg/kg/dose every 8–12 h; prints a higher max (Oeffl 2023 Table 1) review
Adult 400 mg, then 200 mg 2–3 times (max 1.2 g in 1 day); 200–300 mg/8 h (max 1.2 g/day; level 0.8–2.0 mcg/mL) (EHRA 2025 Table 2 as corrected 2026; the original printed 300 mg)
Stop: Known long QT in a shockable rhythm: avoid. With a pulse: slowly, not as a push. Not with procainamide unless a pediatric cardiologist directs.
Class IIIa: non-selective potassium channel block, with sodium, calcium, α and β effects (EHRA 2025 Table 1). All four Vaughan Williams classes; prolongs repolarization without raising dispersion (EHRA 2025).
Oral: sinus rate down 15–20%, PR and QT up about 10%, U waves FDA label. IV: AH and AV nodal refractoriness rise, little or no effect on sinus cycle, QTc or QRS; modest QRS prolongation above 10 mg/kg FDA label. EHRA 2025 describes IV as mainly slowing ventricular conduction: these differ.
PJRT: with a β-blocker, benefit in all treated; alone 75% (Srinivasan 2019, Kang series) review. ARVC: small studies Adult (EHRA 2025).
VF or pulseless VT (AHA/AAP 2025; Korean 2025; Singapore 2026). SVT when other drugs fail (JCS/JHRS 2020; EHRA 2025, Children). Post-operative JET:
Optic neuritis, risk of blindness 1%; corneal deposits over 90%; photosensitivity 25–75%; hypothyroid 5–20%, hyperthyroid 1–5%; CNS 30%; liver enzymes 15–30%; lung 1–10% Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, flutter in AF; torsades under 1% Adult (EHRA 2025 Table 10) (EHRA 2025).
Known long QT in a shockable rhythm: avoid (Singapore 2026) guideline. Avoid giving with procainamide unless a pediatric cardiologist directs it (Korean 2025) guideline. IV: may precipitate VF in AF with an accessory pathway Adult (EHRA 2025)
Contraindicated: cardiogenic shock; marked sinus bradycardia; second- or third-degree AV block without a pacemaker; iodine hypersensitivity FDA label. Oral label adds sick sinus and bradycardia with syncope, without a pacemaker FDA label. Contraindications and safety: bradycardia, QTc over 500 ms, thyroid disorder; IV also hypotension (Breinig 2026 Table 2)
With a perfusing rhythm: slowly, not as a push; in arrest, a push (Korean 2025 Table 2) guideline. Non-post-operative SVT: over 30–60 min, never a direct bolus (Breinig 2026 R19, Table 2) guideline. In children treated for SVT or VT, a bolus given in 20 min or less was a risk factor for collapse (Maghrabi, as cited in Breinig 2026 R19 rationale)
Oral label, boxed: pulmonary and liver toxicity, can be fatal; can worsen arrhythmia; start where continuous ECG and resuscitation are available FDA label
IV: dose-related hypotension, bradycardia, AV block; deaths possibly drug-related (Saul 2005) abstract. Collapse particularly under 3 months with ventricular dysfunction (Geanacopoulos 2024). FDA IV label: pediatric use not recommended.
IV loads sometimes avoided: liver injury, arrest in neonates with cardiac dysfunction (Ciriello 2024). Great care in neonates or low output after CHD surgery (JCS/JHRS 2020). Blood pressure and heart rate during the load (Breinig 2026 R19). Low output: reduce dose and rate; hypotension: slow the rate; IV solution is not suitable for enteral use (Breinig 2026 Table 2). Formulation with benzyl alcohol: neonatal gasping syndrome FDA label. QT over 500 ms: lower dose or stop (EHRA/AEPC 2013 Table 3)
IV with a pulse: Continuous ECG and blood pressure; hypotension or QRS widening: slow or stop (Korean 2025). Thyroid, liver, pulmonary and neurologic status every 6 months; IV: continuous cardiac monitoring (EHRA/AEPC 2013) consensus. Also visual (Oeffl 2023) review
Raises digoxin (reduce 50% or avoid), flecainide, lidocaine, procainamide, warfarin and statins; adds to β-blockers; caution with QT-prolonging drugs (EHRA 2025 Table 15; EHRA/AEPC 2013 Table 3; Geanacopoulos 2024). Grapefruit raises it (Geanacopoulos 2024)
5 mg/kg bolus, max 300 mg, up to 3 doses, max 150 mg for later doses; class IIb, C-LD (AHA/AAP 2025 Figure 2) guideline. The later-dose ceiling only matters above 30 kg (our arithmetic).
Later doses max 300 mg, total 15 mg/kg (Korean 2025 Table 1); max 300 mg (Singapore 2026) guideline: these differ.
5 mg/kg over 20–60 min, max 300 mg; expert consultation strongly recommended first (Korean 2025 Table 2) guideline. AHA/AAP 2025 gives no with-pulse dose; its 150 mg ceiling is for arrest. Peripheral max 2 mg/mL, central max 6 mg/mL (Breinig 2026 Table 2)
SVT: 5 mg/kg, max 150–300 mg, over 60 min, may be repeated once; then 5 mcg/kg/min, by 5 to max 15 mcg/kg/min, max 20 mg/kg/day or 2200 mg/day (Breinig 2026 Table 2) guideline table, ungraded. Its rationale: max 300 mg, repeatable to 15 mg/kg or 450 mg (Breinig 2026 R18 rationale). These differ.
2.5 mg/kg over 10 min; 1 mg/kg/h for 6 h; 0.5 mg/kg/h for 42 h; 2.5 mg/kg again over 10 min for recurrence (JCS/JHRS 2020 Table 78) guideline
Load 10–20 mg/kg/day in 2 doses, max 1200 mg/day, for 4–14 days; then 5–7 mg/kg/day once daily, max 200 mg/day (Breinig 2026 Table 2) guideline table, ungraded
5–10 mg/kg once or twice daily for 1–2 weeks; then 2.5–5 mg/kg once or twice daily (JCS/JHRS 2020 Table 78) guideline
IV 5–10 mg/kg over 60 min, then 10 mg/kg/day (5–15 mcg/kg/min), class IIb (EHRA/AEPC 2013 Tables 1, 2) consensus. 5 mg/kg in 30–60 min, then 5–10 mg/kg/day (Leoni 2023) society review
IV 5 mg/kg over 60 min, then 5–15 mcg/kg/min (Geanacopoulos 2024) review. Infants 5–10 mg/kg over 20–60 min, then 10 mg/kg over 24 h (Ciriello 2024) review
Oral load 10–20 mg/kg/day in 2 doses, max 1200–1600 mg/day (Breinig 2026 R18 rationale) guideline. 10–20 mg/kg/day for 7–10 days, then 5–10 mg/kg/day (Leoni 2023; Ciriello 2024) society review review
Oral 10–15 mg/kg/day for 4–14 days, then 5 mg/kg/day (Geanacopoulos 2024) review. 10 mg/kg/day for 10 days, then 5 mg/kg/day (EHRA/AEPC 2013 Table 3) consensus
IV, 61 children: dose-related hypotension 36%, bradycardia 20%, AV block 15%; 5 deaths at 30 days, 2 possibly drug-related (Saul 2005) abstract
Half-life 30–100 days; hepatic, CYP3A4, which it inhibits, and P-gp (EHRA 2025)
Adult ECG baseline, 1–3 months, yearly; TSH, free T4, free T3 and liver every 6 months; chest X-ray, lung function and eye exam yearly (EHRA 2025 Table 8). Infants: a period of relative hypothyroidism is usual at start (Ciriello 2024)
Adult IV 150 mg in 10 min or 300 mg over 30 min, then 900–1200 mg over 24 h (max 2200 mg/day). Oral 600 mg/day for 2–4 weeks or 1200 mg/day in 3 doses for 2 weeks; then 200 mg/day (max 600 mg/day; USA for VT, max 400 mg/day) (EHRA 2025 Table 2 with the 2026 correction)
Stop: QTc over 450 ms or potassium under 4 mEq/L: contraindicated; start in hospital.
Class IIIa: non-selective potassium channel block; secondary non-selective β-blockade (EHRA 2025 Table 1). D-sotalol blocks IKr; L-sotalol is the β-blocker. Reverse use dependence: effect greatest at slow rates (EHRA 2025).
Sinus cycle length rises; AV nodal conduction slows; atrial, ventricular and accessory pathway refractoriness rises; QT and QTc lengthen with dose FDA label. No effect on conduction velocity in fast-response tissue (EHRA 2025). PR and JT lengthen (JCS/JHRS 2020 Table 6).
Fetal tachyarrhythmia (EHRA 2025, Foetal arrhythmias). RVOT VT with severe symptoms; ARVC in small studies Adult (EHRA 2025).
VT and maintenance of sinus rhythm in AF or flutter (FDA IV label). Flutter and IART after CHD surgery (EHRA/AEPC 2013; Geanacopoulos 2024). SVT (Ciriello 2024; Leoni 2023)
Fatigue 10–20%; dizziness; hypotension; nausea; worsening heart failure 1–3% Adult (EHRA 2025 Table 12). Proarrhythmia high: torsades 0.3–2%, bradycardia Adult (EHRA 2025 Table 10) (EHRA 2025).
Start or restart in hospital with continuous ECG; oral at least 3 days; IV also when up-titrating. Proarrhythmia 0–22% in children; bradycardia, especially with sinus node dysfunction after CHD surgery, may need a pacemaker FDA label. Class I drugs and sotalol: start in hospital (EHRA/AEPC 2013 p 1355) consensus
Contraindicated: QTc over 450 ms or long QT; potassium under 4 mEq/L; sinus bradycardia under 50/min, sick sinus or second- or third-degree AV block without a pacemaker; cardiogenic shock or decompensated heart failure; asthma (FDA IV label) FDA label. Also torsade (Breinig 2026 Table 2); significant LVH, creatinine clearance under 50 mL/min (EHRA/AEPC 2013 Table 3; Ciriello 2024)
QT 500 ms or more: reduce the dose, lengthen the interval or stop (boxed) FDA label (also EHRA/AEPC 2013 Table 3; Ciriello 2024)
Oral label: safety in children not established; the IV label states pediatric indications.
Baseline ECG, potassium, magnesium, creatinine; QTc 2–4 h after each increase; longer intervals in renal impairment FDA label
Renal: adjust dose (EHRA 2025, Children).
Adult Other QT-prolonging drugs; drugs causing low potassium or magnesium. With β-blockers or calcium channel blockers: bradycardia (EHRA 2025 Tables 15, 16)
About 2 years and over, FDA label in two printed forms: 30 mg/m² three times a day (90 mg/m²/day), to a maximum of 60 mg/m²; or 1.2 mg/kg three times a day (3.6 mg/kg/day), to 2.4 mg/kg three times a day. At least 36 h between increases FDA label
The two forms are about equal near 20 kg and not equivalent above it, and the mg/kg form has no cap: at 60 kg it reaches 432 mg/day, above the label’s own comparison of about 360 mg/day (our arithmetic).
About 2 years and under: reduce by an age factor from the label’s graph: 1 month ×0.7 (or 0.68), about 1 week ×0.3, 20 months ×0.97 FDA label
Start, in 3 doses: neonates and infants 2–4; 6 years or under 3–6; over 6 years 2–4 mg/kg/day, max 80 mg/dose; max 8–12 mg/kg/day, 480 mg/day (Breinig 2026 Table 2) guideline table, ungraded. That ceiling is above the label’s 7.2 mg/kg/day (our arithmetic); a review prints max 320 mg/day (below).
Suggested start, mg/kg, normal renal function: 3 days 0.32; 6 days 0.51; 9 days 0.69; 12 days 0.81; 2 weeks 0.9; 3 weeks 1; 1 month–6 years 1.2; 6–12 years 1.1; over 12 years 0.95 (FDA IV label Table 3) FDA label. The table gives no infusion time or interval. Reviews print times and a maximum (below).
Oral 2–8 mg/kg/day in 2 doses; its text gives a narrower start and target, 2–4 mg/kg/day neonates and over 6 years, 3–6 mg/kg/day infants and under 6 years (EHRA/AEPC 2013 Table 3 and text) consensus
Oral 30–60 mg/m²/dose every 8 h, max 320 mg/day (Geanacopoulos 2024) review. 2–8 mg/kg/day every 8–12 h (Leoni 2023) society review; in 2–3 doses, or 90–180 mg/m²/day (Ciriello 2024) review. Neonates start 2 mg/kg/day every 8 h, target 4 mg/kg/day, up to 6 at 1 month (Srinivasan 2019) review
IV 0.2–1.5 mg/kg in 15 min (Leoni 2023) society review. 1 mg/kg over 1 h (max 80 mg); or 80–90% of the oral daily dose in 2–3 doses over 3–5 h (Geanacopoulos 2024) review
Adult Oral 80–160 mg/12 h (max 480 mg/day). IV 1 mg/kg in 10 min, may repeat after 6 h (max 450 mg/day); 75 mg/12 h (EHRA 2025 Table 2). FDA adult IV load is infused over 1 h.
Stop: Not with pre-excitation or VF. Narrow window; IV discouraged in one table.
Class IId: vagal nerve and acetylcholine release activator (EHRA 2025 Table 1). Inhibits Na-K ATPase FDA label; raises vagal tone, activating IK,ACh, inhibiting If and AV nodal ICa,L (EHRA 2025).
Sinus rate slows, AV conduction and refractoriness prolong; atrial refractoriness shortens unevenly (EHRA 2025). PR lengthens, ST depresses FDA label. JT shortens; LV function rises (JCS/JHRS 2020 Table 6). QRS: not stated in sources read.
Fetal tachyarrhythmia, less effective than flecainide for SVT (EHRA 2025, Foetal arrhythmias). AF or flutter rate control Adult (EHRA 2025 Table 4). Does not convert AF or flutter (EHRA 2025).
Infant SVT without WPW: no difference from propranolol in SAMIS (Sanatani 2012) abstract. Second-line combinations (Ciriello 2024). No controlled randomized pediatric studies in atrial tachyarrhythmias FDA label
Nausea, vomiting over 10%; confusion, dizziness 5–10%; yellow vision, halos 5%; fatigue Adult (EHRA 2025 Table 12). Proarrhythmia moderate: AV block, junctional tachycardia, polymorphic VT, atrial tachycardia with block Adult (EHRA 2025 Table 10).
Avoid with pre-excitation (Breinig 2026 Table 2; Ciriello 2024; Escudero 2022): contraindicated with WPW over 1 year; under 1 year the VF risk is not established (EHRA/AEPC 2013) consensus. Contraindicated in ventricular fibrillation FDA label. Also bradycardia, AV block, ventricular arrhythmia, hypertrophic cardiomyopathy, severe electrolyte and acid-base disorders (low potassium, alkalosis), hypothyroidism, pericarditis (Breinig 2026 Table 2)
Narrow therapeutic window. Loading doses should not be given systematically; IV use is discouraged (Breinig 2026 Table 2) guideline table, ungraded. Low potassium or magnesium raises toxicity (Breinig 2026 Table 2). Adjust for renal function (Ciriello 2024). Give IV over 5 min or longer; avoid bolus FDA label. Toxicity: ; do not give calcium (Breinig 2026 Table 2)
Amiodarone, flecainide, propafenone and verapamil raise digoxin: reduce 50% or avoid Adult (EHRA 2025 Table 15; its flecainide row says 25%)
Target 0.8–2.0 ng/mL; in heart failure 0.5–0.8; toxic over 2 (Ciriello 2024) review. Below 0.5 ng/mL less effective; above 2 more toxic without benefit FDA label
Renal: adjust dose (EHRA 2025, Children).
Adult Macrolides raise it (EHRA 2025 Table 15)
Neonates 6–10; infants 8–10; children 10 mcg/kg/day, in 2 doses (Breinig 2026 Table 2) guideline table, ungraded
Infants 10–25 mcg/kg/day; school children 8–20 mcg/kg/day (printed as 0.01–0.025 and 0.008–0.02 mg/kg/day; conversion ours) (JCS/JHRS 2020 Table 78) guideline. These differ.
| Age | IV total load | IV per dose | Oral solution total load | Oral solution per dose |
|---|---|---|---|---|
| Premature | 15–25 | 1.9–3.1 | 20–30 | 2.3–3.9 |
| Full-term | 20–30 | 3–4.5 | 25–35 | 3.8–5.6 |
| 1–24 months | 30–50 | 4.5–7.5 | 35–60 | 5.6–9.4 |
| 2–5 years | 25–35 | 3.8–5.3 | 30–45 | 4.7–6.6 |
| 5–10 years | 15–30 | 2.3–4.5 | 20–35 | 2.8–5.6 |
| Over 10 years | 8–12 | 2.4–3.6 per day, once daily | 10–15 | 3.0–4.5 per day, once daily |
Oral: neonates 5–8; infants 10–15; 2–10 years 8–10; over 10 years 3–5 mcg/kg/day (EHRA 2025 Table 18; not in the 2013 statement it cites) consensus
Term neonates and infants: load 30–40 mcg/kg over 24 h; 8–12 mcg/kg/day in 2 doses (Ciriello 2024) review. Neonates 8–10 mcg/kg/day every 12 h (Srinivasan 2019) review
Adult IV 0.25–0.5 mg, then more (max 1.5 mg/day). Oral load 0.5–0.75 mg in 2 doses 6 h apart; 0.25 mg/day (EHRA 2025 Table 2)
Stop: IV: not in wide-complex VT or pre-excited AF/flutter; wide QRS: diagnosis first; not under 1 year (one table: 2).
Class IVa: L-type calcium channel blocker (EHRA 2025 Table 1). Also α (JCS/JHRS 2020 Table 6). Suppresses abnormal automaticity in depolarized cells and EAD-triggered activity (EHRA 2025).
AV conduction slows and AV nodal refractoriness rises, rate-related FDA label. No change in atrial or ventricular muscle or His-Purkinje conduction (EHRA 2025). Sinus rate falls, PR lengthens, LV function falls (JCS/JHRS 2020 Table 6). QT: not stated in sources read.
Left fascicular VT, including posterior fascicular VT Adult (EHRA 2025 and Children). SVT after adenosine, without pre-excitation Adult (EHRA 2025). Short-coupled torsades Adult (EHRA 2025).
SVT over 1 year after adenosine, with a pediatric cardiologist (Korean 2025). Verapamil-sensitive VT over 1 year (JCS/JHRS 2020 Table 72). Left fascicular and RVOT VT (Escudero 2022)
Constipation 10%; hypotension, dizziness; headache; worsening heart failure Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
IV contraindicated: wide-complex VT (QRS ≥0.12 sec), marked deterioration and VF; proper diagnosis first is imperative. Also second- or third-degree AV block or sick sinus without a pacemaker; flutter or AF with an accessory pathway; within a few hours of an IV β-blocker; severe hypotension, shock, severe heart failure unless from an SVT amenable to verapamil FDA label. Oral label adds severe left ventricular dysfunction; systolic under 90 mm Hg Adult FDA label. Also sinus bradycardia, conduction disorder (Breinig 2026 Table 2)
Severe, sometimes fatal hemodynamic events in neonates and infants FDA label. Under 1 year: contraindicated (EHRA/AEPC 2013; JCS/JHRS 2020; Ciriello 2024; Breinig 2026 text); over 1 year only (Korean 2025).
Under 2 years: “Do not use” (Breinig 2026 Table 2) guideline table, ungraded. Its table and its text differ, and it says calcium channel blockers should probably not be used in children (Breinig 2026 R17). EHRA 2025 consensus, an adult document, makes an exception for posterior fascicular VT even under 1 year.
Contraindicated with pre-excitation; IV not recommended with compromised cardiac function or long-term β-blockers (EHRA/AEPC 2013). Myocardial depression, hypotension or arrest; consult a pediatric cardiologist first (Korean 2025). Caution in undifferentiated wide-QRS tachycardia (Escudero 2022)
IV: under continuous ECG and blood pressure monitoring FDA label
Adult Raises digoxin and procainamide; raises CYP3A4 and P-gp substrates (EHRA 2025 Table 15)
Over 1 year: 0.1–0.3 mg/kg (Korean 2025) guideline. 1–15 years: 0.1–0.3 mg/kg over at least 2 min, max 5 mg; repeat at 30 min, max 10 mg; under continuous ECG and blood pressure monitoring FDA label. 0.1 mg/kg over 5 min (JCS/JHRS 2020 Table 78) guideline
Teenager: 1–5 mg/dose slow over 5 min, repeat if needed, max 10 mg total, under continuous monitoring (Breinig 2026 Table 2) guideline table, ungraded
The FDA label still prints, for 0–1 year, beneath the warning above: 0.1–0.2 mg/kg (usual 0.75–2 mg) over at least 2 min under continuous ECG and blood pressure monitoring FDA label
3–6 mg/kg/day in 3 doses (JCS/JHRS 2020 Table 78) guideline. Teenager: 80–160 mg/day in 3 doses, max 480 mg/day (Breinig 2026 Table 2) guideline table, ungraded
IV 0.1 mg/kg slowly over 2 min, class I, B, not under 1 year (EHRA/AEPC 2013 Table 1) consensus. 0.1–0.2 mg/kg in 5–10 min (Leoni 2023) society review
Oral 4–8 mg/kg/day in 3 doses (EHRA/AEPC 2013 Table 3) consensus. 2–8 mg/kg/day every 8 h (Leoni 2023) society review. 2–9 mg/kg/day every 8 h; max 120–480 mg/day (Oeffl 2023 Table 5) review
EHRA 2025 consensus: avoid under 1 year, yet the treatment of choice for posterior fascicular VT even at this age, usable safely in acute settings; reported cases had heart failure, overdosing or other drugs, and “some controversy exists”.
Adult IV 2.5–5 mg in 2 min, then 5–10 mg in 15 min if needed; 2–4 mg/h (max 100 mg/day). Oral 80–120 mg IR/8 h or 180–240 mg ER/day (max 480 mg/day) (EHRA 2025 Table 2)
Stop: Not in VT or pre-excited AF/flutter; wide QRS: diagnosis first; not under 1 year, under 2 in one table.
Class IVa: L-type calcium channel blocker (EHRA 2025 Table 1). Use-dependent at the AV node FDA label.
AV nodal conduction time and refractoriness rise; sinus cycle length rises; no significant effect on fast sodium channel-dependent tissue FDA label. Sinus rate falls, PR lengthens (JCS/JHRS 2020 Table 6). QT: not stated in sources read.
Stable SVT after adenosine, without pre-excitation; AF or flutter rate control Adult (EHRA 2025).
Stable SVT unresponsive to vagal maneuvers or adenosine; rate control of atrial tachyarrhythmias; may be effective in fascicular VT (Geanacopoulos 2024), but the label contraindicates IV diltiazem in VT: these differ
Edema 10%; hypotension, dizziness; headache; worsening heart failure Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block Adult (EHRA 2025 Table 10).
IV contraindicated: ventricular tachycardia, accurate diagnosis first in wide QRS; sick sinus or second- or third-degree AV block without a pacemaker; AF or flutter with an accessory tract; severe hypotension or cardiogenic shock; within a few hours of an IV β-blocker FDA label. Also sinus bradycardia, conduction disorder (Breinig 2026 Table 2)
Under 1 year: considered contraindicated (EHRA/AEPC 2013; Breinig 2026 text); should not be used, fatal hypotension is reported (Oeffl 2023) review.
Under 2 years: “Do not use” (Breinig 2026 Table 2) guideline table, ungraded. Its table and its text differ, and it says calcium channel blockers should probably not be used in children (Breinig 2026 R17).
Contraindicated with pre-excitation (EHRA/AEPC 2013). Bradycardia, AV block, hypotension, shock in overdose. Titrate to heart rate and blood pressure (Geanacopoulos 2024)
Grapefruit raises it (Geanacopoulos 2024). Adult Raises CYP3A4 and P-gp substrates; with β-blockers, AV block (EHRA 2025 Tables 15, 16)
Teenager: 0.25 mg/kg/dose, max 20 mg, slow over 2 min; refractory arrhythmia 5–15 mg/h (Breinig 2026 Table 2) guideline table, ungraded. No guideline dose for younger children read.
FDA IV label: not established; no dose.
IV 0.25 mg/kg over 5 min, then 0.05–0.15 mg/kg/hour (Geanacopoulos 2024) review. 0.25 mg/kg (max 20 mg), then 0.05–0.25 mg/kg/h (max 15 mg/h) (Oeffl 2023 Table 5) review
Oral 1.5–2 mg/kg/day in 3–4 doses (max 360 mg/day) (Geanacopoulos 2024) review. Oeffl 2023 review prints a per-dose range whose top exceeds its own daily maximum; not shown.
Adult IV 0.25 mg/kg in 2 min, then 0.35 mg/kg if needed; 5–15 mg/h. Oral 60 mg/8 h or 120–360 mg ER/24 h (max 480 mg/day) (EHRA 2025 Table 2)
Stop: Not with pacemaker dependence, significant bradycardia or hypotension, or strong CYP3A4 inhibitors.
Class 0: HCN channel, If blocker (EHRA 2025 Table 1). Slows sinus node depolarization without significantly affecting contractility (EHRA 2025).
Effects greatest at the sinus node; PR and AH can lengthen; uncorrected QT rises with slowing, without rate-corrected prolongation FDA label. EHRA 2025 says no significant AV conduction effect: these differ. QRS: not stated in sources read.
JET: . Inappropriate sinus tachycardia Adult (EHRA 2025 Table 4). Not advised with paroxysmal AF Adult (EHRA 2025).
Post-operative and congenital JET, emerging (EHRA 2025, Children). Rate slowing as a second stage in SVT with cardiomyopathy (Breinig 2026 R20, expert opinion)
Phosphenes 2–14%; hypertension 8%; fatigue 5%; CNS 5% Adult (EHRA 2025 Table 12). Proarrhythmia low: bradycardia, AV block, AF Adult (EHRA 2025 Table 10).
Contraindicated: pacemaker dependence; sick sinus, sinoatrial or third-degree AV block without a demand pacemaker; clinically significant hypotension or bradycardia; acute decompensated heart failure; severe hepatic impairment; strong CYP3A4 inhibitors FDA label. Label: heart failure only, not established under 6 months FDA label. Also AV block, bradycardia (Breinig 2026 Table 2)
Oral only; absorption is affected once cardiac output falls, so early use before compromise (Sasikumar 2021) review
Negative chronotropes, including amiodarone, raise the risk of bradycardia. Bradycardia: reduce; consider 0.02 mg/kg twice daily if it appears at the start dose. Avoid moderate CYP3A4 inhibitors and inducers. Monitor heart rate; label target a fall of at least 20% FDA label
Under 6 months: start 0.02 mg/kg/dose twice daily. 6 months and over: 0.05 mg/kg/dose, max 2.5 mg, twice daily; every 1–2 weeks to max 0.3 mg/kg/dose, max 7.5 mg (Breinig 2026 Table 2) guideline table, ungraded
6 months and over, under 40 kg: 0.05 mg/kg twice daily with food; adjust every 2 weeks by 0.05 mg/kg; max 0.2 mg/kg twice daily under 1 year, 0.3 mg/kg twice daily from 1 year, up to 7.5 mg. Over 40 kg: 2.5 mg twice daily, max 7.5 mg (FDA, heart failure) FDA label
From 6 months to 1 year, Breinig stops at 0.3 mg/kg/dose and the label at 0.2: these differ.
0.05–0.1 mg/kg/dose twice daily (Balweel 2026, meta-analysis, N = 87). JET cohorts include younger infants than the label covers.
0.1 mg/kg/dose twice daily; a second dose at 6 h if no response; given alone only if hemodynamically stable (Kamali 2024, n = 26).
Adult Oral 5–7.5 mg/12 h (EHRA 2025 Table 2)
Stop: Heart block or myocardial damage: contraindicated on about half of IV labels.
Outside the Vaughan Williams classes (EHRA 2025). Exerts Ca2+ channel-blocking and membrane-stabilizing effects (Lei 2018 p 1893).
Not stated in sources read.
Torsades (Korean 2025; JCS/JHRS 2020; Escudero 2022). Prevention of post-operative JET, risk ratio 0.50 (0.39–0.66) (Mendel 2022)
Vasodilation; hypotension if given fast (Korean 2025). Proarrhythmic risk: not stated in sources read.
Heart block or myocardial damage: contraindicated on about half of IV labels; dextrose premix adds diabetic coma, myasthenia gravis; others list only toxemia of pregnancy FDA label
Vasodilation. In torsades, rapidly, over several minutes. General rate: over 10–20 min. Rapid administration may cause hypotension (Korean 2025 text, Table 2). Labels, which do not address torsades: too fast can also cause hypermagnesemia FDA label. JET: rate not stated in sources read.
Torsades: 25–50 mg/kg over several minutes, max 2 g (Korean 2025) guideline. 50 mg/kg, max 2 g (Singapore 2026 Figure 5) guideline. 20–40 mg/kg over 1–2 min, then 0.05–0.3 mg/kg/min (JCS/JHRS 2020 Table 78) guideline. Over several minutes (Korean), over 1–2 min (JCS Table 78), 30–40 mg/kg over 5–10 min (JCS text; its worked example is an adult): these differ, and rapid administration may cause hypotension.
Label rate, no age or weight stated: “should generally not exceed 150 mg/minute”, except in severe eclampsia with seizures FDA label. Not a torsades rate: no label read mentions torsades. Not weight-based: at 3 kg, 50 mg/kg would run in 1 min; at 2 g, about 13 min, against several minutes for torsades and 10–20 min otherwise (Korean 2025; our arithmetic).
JET prevention in trials: 30 mg/kg IV or 25 or 50 mg/kg via the bypass circuit. JET treatment: 25–50 mg/kg (Mendel 2022, meta-analysis)
Wide QRS of unknown mechanism: class IIb, no dose given (EHRA/AEPC 2013 Table 2) consensus
Adult 1–2 g in 5 min; 0.5–1 g/h. This is not a pediatric dose (EHRA 2025 Table 2)
Altered mental status, shock or hypotension. Narrow QRS (≤0.09 sec): adenosine if IV or IO access is present, or synchronized cardioversion. Wide QRS (>0.09 sec): synchronized cardioversion (AHA/AAP 2025 Figure 7) guideline. Sedate if needed, with extreme caution in choice and dose; do not delay cardioversion (AHA/AAP 2025 Figure 7, text). Doses:
Cardioversion 0.5–1 J/kg, then 2 J/kg (AHA/AAP 2025 Figure 7, class IIa, C-LD; Korean 2025 Table 4) guideline
1 J/kg, then 2 J/kg; start with adenosine and cardiovert rapidly if it fails; flutter, cardioversion first (Breinig 2026 R14, R15, expert opinion) guideline. Range 0.5–2 J/kg (JCS/JHRS 2020) guideline
Vagal maneuvers first, then adenosine if IV or IO access is ready; each class I, C-LD (AHA/AAP 2025) guideline. Infants: ice to the face (Ciriello 2024) review. Doses:
Expert consultation, class I, C-EO; few comparative studies; the risk of proarrhythmia and collapse rises with each added agent. With compromise, no response and no expert available: IV procainamide, amiodarone or sotalol may be considered, class IIb, C-LD (AHA/AAP 2025) guideline
IV procainamide should probably be used, amiodarone if it is unavailable, and calcium channel blockers probably not (Breinig 2026 R17, GRADE 2+, non-post-operative SVT in PICU) guideline. Amiodarone over 30–60 min, never as a direct bolus (Breinig 2026 R19)
Avoid amiodarone and procainamide together unless a pediatric cardiologist directs it (Korean 2025) guideline
With tachycardia-induced cardiomyopathy, slow the rate first rather than convert; contact an ECMO center if refractory with shock (Breinig 2026 R13, R8, expert opinion) guideline
Transesophageal overdrive pacing or synchronized cardioversion, class I, B. Stable: digoxin, adding flecainide or amiodarone, class IIa, B (EHRA/AEPC 2013) consensus
IV amiodarone: cardiovascular collapse, particularly under 3 months with ventricular dysfunction (Geanacopoulos 2024); sudden arrest in neonates with significant cardiac dysfunction (Ciriello 2024). Class Ic: not with reduced LVEF (EHRA 2025 Table 18). Verapamil:
WPW with recurrent SVT under 15 kg: class Ic I; sotalol or class IA IIa; β-blocker, amiodarone or ablation IIb; all level C (JCS/JHRS 2020 Table 70) guideline
SAMIS randomized trial, infants under 4 months, no WPW: recurrence 19% digoxin, 31% propranolol (P = 0.25); no first recurrence after 110 days of treatment (Sanatani 2012) abstract. Doses: open each drug below.
Digoxin, verapamil and diltiazem are contraindicated with pre-excitation; whether oral digoxin carries a substantial VF risk under 1 year is not established (EHRA/AEPC 2013) consensus
β-blockers in pre-excited AF: contraindicated, VF risk, III: Harm, B-NR Adult (ACC/AHA 2023); “not recommended”, III, level B Adult (ESC 2019). Children with WPW: AV nodal suppression risks rapid conduction during AF (JCS/JHRS 2020). In pre-excited AF, adenosine or other AV nodal blockers can result in degeneration to VF (Escudero 2022) review.
Antidromic AVRT, wide QRS: IV β-blocker “should be avoided” Adult (JCS/JHRS 2020).
Acute orthodromic AVRT only, manifest or concealed pathway: IV esmolol or metoprolol IIa, level C if vagal maneuvers and adenosine fail, without decompensated heart failure (ESC 2019); discouraged with known pre-excitation (EHRA 2025) consensus: these differ Adult. No pediatric source read explicitly permits IV use with pre-excitation.
Prophylaxis of SVT with pre-excitation: sources disagree. For: β-blocker IIb, level C under 15 kg, not listed for recurrent SVT from 15 kg (JCS/JHRS 2020 Table 70); propranolol typical first line under 20 kg (ACC.org 2025) expert analysis: . Against: “contraindicated” (EHRA/AEPC 2013) consensus; discouraged Adult (EHRA 2025) consensus; β-blocker only without pre-excitation on ECG: I, level A, caution even if intermittent Adult (JCS/JHRS 2020); IIa, level B Adult (ESC 2019).
Propranolol labels: beta-adrenergic blockade in WPW with tachycardia “has been associated with severe bradycardia requiring treatment with a pacemaker” FDA label
0.5 J/kg, then 1–2 J/kg (Ciriello 2024) review. Neonates: 0.25 J/kg orthodromic reentry or AVNRT, 0.5 J/kg flutter, 1–2 J/kg AF, doubling each attempt (Srinivasan 2019) review
Recurrent SVT, median age 34 days, 40 episodes: procainamide 71%, amiodarone 34% (P = 0.046), full and partial success combined (Chang 2010, retrospective) abstract
Flecainide 1–2 mg/kg over 5 min; propafenone 1–2 mg/kg over 2 h; amiodarone 5–10 mg/kg over 20–60 min, then 10 mg/kg over 24 h; esmolol 0.5 mg/kg bolus, then 50–200 mcg/kg/min (Ciriello 2024 Table 1) review. Breinig 2026 Table 2 says no esmolol loading dose in children guideline table, ungraded
Propranolol 1–5 mg/kg/day in 3 doses; digoxin 8–12 mcg/kg/day in 2 doses; flecainide 2–7 mg/kg/day in 2 doses; propafenone 10–15 mg/kg/day in 3 doses; sotalol 2–8 mg/kg/day in 2–3 doses; amiodarone 10–20 mg/kg/day for 7–10 days, then 5–10 mg/kg/day (Ciriello 2024 Table 2, oral) review. Other sources differ: open each drug.
AF: ACC/AHA 2023 Section 10.6, recommendation 4, names β-blockers, for VF or hemodynamic deterioration; “Data are very limited and observational”. Its reference 11 is a single case: a 20-year-old man in AF with no clear pre-excitation on the first ECG received IV diltiazem 25 mg (then short runs read as nonsustained VT), then IV metoprolol 15 mg over 15 minutes and diltiazem 5 mg/hour; 30 minutes later, intermittently pre-excited AF, mean rate 120 bpm or less, turned into VF after a pre-excited R-R of 250 ms; one shock restored rhythm, and a left lateral pathway was ablated. The authors attribute it to the two drugs together, so the β-blocker’s part cannot be separated. The authors add: no pre-excitation during AF does not necessarily exclude a high-risk pathway; if AV nodal blockers given for AF unmask WPW, stop them and use electrical cardioversion or IV ibutilide Adult (Kim 2008) case report. ESC 2019 p 690, repeated p 704, “potentially harmful”, is a chronic-therapy row; the text on p 690 covers acute pre-excited AF and names β-blockers. Its reference 427: IV propranolol 0.2 mg/kg during AF induced at electrophysiology study, 10 patients with WPW, mean age 36 years, none with prior cardiac arrest: mean ventricular rate fell by 15–56 bpm in 6, stayed within 10 bpm in 3 and rose from 203 to 267 bpm in 1, after 5 mg, when the infusion was stopped; that patient had 54% narrow QRS complexes; group mean 178 bpm before, 165 after, not significant. The paper is inconsistent: its abstract says propranolol is not for AF when most QRS complexes are pre-excited, its conclusion that it can be used safely only when most are; its data show the rise when most were narrow Adult (Morady 1987) small study. In AF with an accessory pathway, β-blockers facilitate conduction over the pathway and raise the ventricular rate; it “may shift to ventricular fibrillation” Adult (JCS/JHRS 2020 2.4.2) guideline. Children with WPW: “a risk of rapid conduction to the ventricles during AF” (JCS/JHRS 2020 11.1.4.2) guideline.
Acute: ESC 2019 p 690, table for AVRT “due to manifest or concealed accessory pathways”. EHRA 2025, PSVT, intravenous, for the risk if AF occurs. JCS/JHRS 2020 Table 15, footnote.
Prophylaxis: EHRA/AEPC 2013 p 1355, in its text, no class. EHRA 2025, AVRT prevention, for the risk if AF occurs.
JCS/JHRS 2020 Table 70, WPW: recurrent or symptomatic SVT under 15 kg, β-blocker IIb, level C. At 15 kg or more: β-blocker IIb, level C after aborted sudden death, syncope or decreased cardiac function; no β-blocker row for recurrent persistent SVT induced on electrophysiology study, or palpitations. In children with pre-excitation syndrome, class IC, IA or III drugs “are preferred” (JCS/JHRS 2020 11.1.4.2) guideline. Leoni 2023, ages 0–12, prophylaxis for WPW and PSVT together, pre-excitation not specified: “Class IC drugs and amiodarone can also be used in combination with beta blockers” society review. JCS/JHRS 2020 Table 16, “in patients without manifest (including intermittent) WPW syndrome”, and 4.3 Adult. ESC 2019 p 690, “if no signs of pre-excitation are present on resting ECG” Adult.
Practice, not advice: a survey of North American pediatric cardiologists, published 2006, 295 of 1534 with complete data, infants with pre-excitation: acute, propranolol 34%, esmolol 17%; chronic, propranolol 70%, atenolol 6% (Wong 2006, abstract; reported in Srinivasan 2019) review.
No differences in effectiveness between medications (Wei 2022, registry and literature, 2534 infants). Duration: most give 6–12 months, without clear evidence (EHRA/AEPC 2013) consensus; earlier stopping is suggested for low-risk infants (Ciriello 2024) review
Class, level: reduce catecholamines, atrial overdrive pacing, hypothermia, deep sedation I, C; ECMO for collapse I, C; IV amiodarone I, C; IV landiolol IIa, C; IV nifekalant or procainamide IIb, C (JCS/JHRS 2020 Table 71) guideline. It gives no JET-specific doses; general doses are under each drug.
Amiodarone, IV or oral, recommended as the first line therapy; if unsatisfactory, combine with digoxin, a β-blocker or flecainide, class I, B (EHRA/AEPC 2013) consensus. Its figures, 62% needing combinations and 11% converted by drugs alone, are from a non-post-operative JET series it cites, not from post-operative JET.
Reduce catecholamines, correct fever, atrial pacing to restore synchrony (Walsh 1997) abstract. Sedate, cool, atrial or AV sequential pacing (Sasikumar 2021) review
Cardioversion does not work; digoxin, β-blockers and calcium channel blockers are described as ineffective (Sasikumar 2021) review. Oeffl 2023 review lists esmolol for JET, and EHRA/AEPC 2013 consensus adds digoxin or a β-blocker to amiodarone: these conflict.
| Drug | Result | Source |
|---|---|---|
| Ivabradine vs amiodarone | Sinus rhythm 95.8% vs 93.5%, difference 2.3% (95% CI −6.7 to 11.5). Median to sinus 22 vs 21.5 h. Rate control later with ivabradine: 8.0 vs 7.0 h | Arvind 2021, open-label RCT, n = 94 abstract |
| Ivabradine | Conversion 98.8% (95% CI 93.8–100); 48.3% also on another antiarrhythmic. Authors call these exploratory | Balweel 2026, single-arm meta-analysis, 5 studies, N = 87 |
| Ivabradine: alone 14, with amiodarone 10, with flecainide 2 | Alone if hemodynamically stable; with amiodarone if likely to deteriorate. Median rate control 12 h, sinus 55.5 h | Kamali 2024, uncontrolled, n = 26 |
| Amiodarone IV | Faster with higher dose overall, not significant within JET. Adverse events 87%; 2 deaths possibly drug-related | Saul 2005, RCT, n = 61 (JET 31) abstract |
| Procainamide | Below 180/min in 3.2 h with the higher load, 6.4 h with the lower (p<0.02) | Mandapati 2000, n = 17 abstract |
| Procainamide with hypothermia | Controlled 70 of 71 overall; correction of fever and this combination appeared efficacious | Walsh 1997, staged protocol abstract |
| Sotalol IV | Reported as useful; not compared | Sasikumar 2021 review |
Risk ratio for JET: amiodarone 0.34 (0.19–0.60), dexmedetomidine 0.34 (0.21–0.52), magnesium 0.50 (0.39–0.66) (Mendel 2022 abstract, meta-analysis, small studies)
RCT, under 12 years: JET 8.5% amiodarone from induction, no bolus, for 48 h; 14.2% dexmedetomidine; 24.7% controls (P = 0.022) (Wadile 2023)
Ivabradine 0.1 mg/kg every 12 h (Arvind 2021, as listed in Balweel 2026 Table 1); amiodarone dose not in the abstract.
Ivabradine 0.05–0.1 mg/kg/dose twice daily (Balweel 2026).
Ivabradine 0.1 mg/kg twice daily; with amiodarone 10 mg/kg/day, usually no load (Kamali 2024).
Amiodarone IV: three regimens; doses not in the abstract (Saul 2005) abstract.
Procainamide load 3 mg/kg over 20 min or 10 mg/kg; infusion 40–120 mcg/kg/min (Mandapati 2000) abstract. With hypothermia: doses not in the abstract (Walsh 1997) abstract.
Sotalol IV 1 mg/kg over 1 h (Sasikumar 2021) review.
Prevention: amiodarone 5–10 mcg/kg/min; dexmedetomidine 0.2–0.5 mcg/kg/h (Wadile 2023).
Sasikumar 2021 review: its text says amiodarone “has emerged as the first-line agent”; its abstract says “Amiodarone and procainamide remain the preferred drugs”. EHRA 2025 consensus: ivabradine monotherapy may be an alternative to amiodarone, or an adjunct when refractory.
No pediatric dose specific to this arrhythmia in any source read. PACES/HRS 2014 and EHRA/AEPC 2018, which would carry drug recommendations, could not be read. General doses: ,
Late flutter after CHD surgery does not settle by itself. Long-term drug management has been disappointing, favoring catheter ablation. Amiodarone: considerable side effects, including a slower atrial rate making 1:1 conduction more likely. Sotalol: of some value in a small post-operative pediatric group, recurrence high (EHRA/AEPC 2013) consensus
Adult Class I drugs do not terminate flutter and raise the risk of 1:1 conduction; termination is advised with selective class III drugs or cardioversion (EHRA 2025, term: macro re-entrant atrial tachycardia) consensus
Oral high-dose propafenone: 0 of 5 IART episodes converted, all in CHD (Przybylski 2023, cohort, median age 22.8 years). Flecainide may not be safe in children with structurally abnormal hearts and flutter (Perry 1992) review abstract.
Commonly used for flutter and IART after CHD surgery (Geanacopoulos 2024) review
Mixed SVT including IART, median age 34 days: procainamide 71%, amiodarone 34% (Chang 2010) abstract. Not IART alone.
Adult First-onset SVT, n = 92: class III drugs (85% sotalol) had less recurrence, HR 0.5 (95% CI 0.27–0.96); adverse effects 22%, mainly amiodarone (Koyak 2013) abstract
Adult Dofetilide, n = 64 (IART 45%): major inpatient events 4.7%; 49% still on drug at 3 years (El-Assaad 2016, PACES) abstract. Dose 125–500 mcg/12 h by QT and creatinine clearance (EHRA 2025 Table 2)
First shock 2 J/kg, second 4 J/kg, then ≥4 J/kg, max 10 J/kg or adult dose (AHA/AAP 2025 Figure 2) guideline. An initial 2–4 J/kg is reasonable (AHA/AAP 2025, class IIa, C-LD; Singapore 2026) guideline
Amiodarone 5 mg/kg bolus, max 300 mg, up to 3 doses, max 150 mg for later doses; or lidocaine 1 mg/kg; either may be considered, class IIb, C-LD (AHA/AAP 2025 Figure 2) guideline. The later-dose ceiling only matters above 30 kg (our arithmetic).
Later amiodarone doses: max 300 mg each, total 15 mg/kg (Korean 2025 Table 1); max 300 mg (Singapore 2026) guideline: these differ. Lidocaine max 100 mg, then 20–50 mcg/kg/min (Singapore 2026) guideline
Known long QT in a shockable rhythm: avoid amiodarone; early defibrillation and IV magnesium (Singapore 2026) guideline. Observational data: neither drug significantly changed survival to discharge (AHA/AAP 2025)
Wide QRS (>0.09 sec). Synchronized cardioversion urgently, whatever the suspected origin: 0.5–1 J/kg, then 2 J/kg, class IIa, C-EO (AHA/AAP 2025 Figure 7; Korean 2025 Table 4) guideline. 1–2 J/kg, up to 4 J/kg (JCS/JHRS 2020) guideline. Sedate if needed, with extreme caution in choice and dose; do not delay cardioversion (AHA/AAP 2025 Figure 7, text)
Expert consultation before further drugs (AHA/AAP 2025 Figure 7); that figure prints no amiodarone dose with a pulse. Amiodarone with a perfusing rhythm: slowly, expert consultation strongly recommended first (Korean 2025 Table 2) guideline
Wide: >0.09 sec (AHA/AAP 2025 Figure 7). SVT with aberrancy is the most common cause in children. Expert consultation first, class I, C-LD. Adenosine, with that consultation, if regular and monomorphic, class IIa, C-EO; if irregular it may be pre-excited AF, and adenosine can lead to VF. No support for or against a specific drug (AHA/AAP 2025) guideline
IV lidocaine, nifekalant or amiodarone; great care with IV amiodarone in neonates or low output after CHD surgery (JCS/JHRS 2020) guideline. IV amiodarone may precipitate VF in AF with an accessory pathway Adult (EHRA 2025). Lidocaine should not be used in Wolff-Parkinson-White FDA label
IV verapamil is contraindicated in wide-complex VT (the label’s cut-off, QRS ≥0.12 sec; Figure 7’s wide starts above 0.09 sec): marked deterioration and VF. IV diltiazem likewise in VT, accurate diagnosis first in wide QRS FDA label
FDA contraindication above: the label requires a proper diagnosis before IV verapamil. Verapamil-sensitive VT over 1 year: verapamil class I, level C; β-blocker if verapamil cannot be used (JCS/JHRS 2020 Table 72) guideline. Age limits differ:
Magnesium (Korean 2025; Singapore 2026; JCS/JHRS 2020) guideline. Doses below. Give rapidly, over several minutes; rapid administration may cause hypotension. If it becomes VF or pulseless VT: CPR and defibrillation as soon as possible (Korean 2025)
High-dose β-blocker; IV β-blocker for repetitive VT; deep sedation if it persists; flecainide proposed if not controlled (EHRA/AEPC 2013) consensus. Bidirectional VT: esmolol (Escudero 2022) review
β-blockers may be pro-arrhythmic in this type; mexiletine or flecainide may be of use (EHRA/AEPC 2013) consensus. Flecainide add-on if QTc >500 ms Adult (EHRA 2025) consensus
Class I drugs are not recommended with structural disease or systolic dysfunction (EHRA/AEPC 2013; EHRA 2025, Children) consensus. Prophylactic use is potentially harmful in adult CHD with asymptomatic ventricular arrhythmia Adult
With a perfusing rhythm: 5 mg/kg over 20–60 min, max 300 mg (Korean 2025 Table 2) guideline
25–50 mg/kg over several minutes, max 2 g (Korean 2025) guideline. 50 mg/kg, max 2 g (Singapore 2026 Figure 5) guideline. 20–40 mg/kg over 1–2 min, then 0.05–0.3 mg/kg/min (JCS/JHRS 2020 Table 78) guideline. Over several minutes against 1–2 min: these differ.
Compromise: 1–2 J/kg, doubling each attempt (EHRA/AEPC 2013) consensus. If still unstable, amiodarone 5 mg/kg slow bolus over 20–60 min or lidocaine 1 mg/kg (Escudero 2022) review
Stable: lidocaine IIa, C; amiodarone, procainamide, esmolol bolus 500 mcg/kg and magnesium IIb (EHRA/AEPC 2013 Table 2) consensus; Breinig 2026 Table 2 says no esmolol loading dose in children. Options include IV amiodarone, procainamide, lidocaine, esmolol (Escudero 2022) review. Esmolol with magnesium, “provided that antidromic conduction through an accessory AV pathway has been excluded” (EHRA/AEPC 2013 p 1352) consensus
RVOT VT: IV verapamil or β-blocker. Left fascicular VT: stable children over 12 months; expert consultation first (Escudero 2022) review. EHRA 2025 consensus calls verapamil the treatment of choice for posterior fascicular VT even under 1 year; JCS/JHRS 2020 and EHRA/AEPC 2013 exclude infants.
Correct potassium and calcium; temporary pacing if bradycardic; isoproterenol in acquired long QT; β-blocker in congenital long QT (Escudero 2022) review. Polymorphic VT: IV propranolol, deep sedation, potassium and magnesium IIb, C (EHRA/AEPC 2013 Table 2) consensus
If symptomatic: propranolol 1 mg/kg/day; if severe, flecainide 2–4 mg/kg/day (EHRA/AEPC 2013) consensus
In pediatric patients with structural heart disease, flecainide has been associated with cardiac arrest and sudden death. Start in hospital with rhythm monitoring; a cardiologist skilled in pediatric arrhythmias supervises FDA label
Neither flecainide nor propafenone should be used in children with structural heart disease (EHRA/AEPC 2013) consensus. Young patients on flecainide or encainide: cardiac arrest and death mostly with underlying heart disease; flecainide for SVT 8.3% vs 0.3% (p<0.001) (Fish 1991, 579 patients, 36 institutions) abstract
Oral propafenone, 772 children: adverse cardiac events 4.8% with structural disease, 1.5% without; acceleration of ventricular rate during atrial flutter in 1 patient; 21 were treated for flutter (Janousek 1998) abstract
No pediatric source read gives a rate of 1:1 conduction or tests pairing in children; the search was not systematic. On proarrhythmic fears from adults, “this appears less relevant among children” (EHRA/AEPC 2013) consensus. Our note: the same statement bars class Ic with structural heart disease, so this cannot cover it.
Adult Flecainide and propafenone can turn AF into flutter, and lengthen the flutter cycle (to 240–360 ms; by about 100 ms without ending the tachycardia). The slower atrial rate lets the AV node conduct 1:1, and class I drugs have only a weak effect at the node (EHRA 2025) consensus
Adult Rapid wide bizarre QRS from aberrancy, easily mistaken for VT; can cause instability. Exercise or stress may unmask it (EHRA 2025) consensus
Class Ic should be combined with a β-blocker to enhance efficacy and reduce the risk of one-to-one conduction if flutter occurs (EHRA/AEPC 2013, pediatric, AVNRT without structural disease) consensus. The same statement says β-blockers are contraindicated with pre-excitation.
Adult AV blocking agents can prevent it; it is common to add a β-blocker, verapamil or diltiazem to prophylactic class Ic, but not with amiodarone, which may itself give enough AV block. Advise avoiding exercise during breakthrough episodes even with an add-on (EHRA 2025) consensus. EHRA/AEPC 2013 says amiodarone’s slowing of the atrial rate makes 1:1 conduction more likely. Different settings; both effects are described.
Adult Digoxin or β-blockers may lower the risk FDA label. Digoxin: avoid with pre-excitation (EHRA/AEPC 2013), and flecainide raises digoxin levels (EHRA 2025 Table 15)
EHRA/AEPC 2013 calls β-blockers contraindicated with pre-excitation consensus, yet class Ic and amiodarone can be used with β-blockers (Leoni 2023, WPW and accessory pathways) society review: sources differ.
β-blocker with calcium channel blocker is listed as potentially hazardous (AV block) Adult (EHRA 2025 Table 16). IV verapamil or IV diltiazem within a few hours of an IV β-blocker is contraindicated FDA label. Sources advise against verapamil and diltiazem under 1 year, and one table under 2 years: .
Adult The class Ic drug is advised to be stopped; cavotricuspid isthmus ablation is called a treatment of choice. EHRA 2025 consensus calls progression to true VT or VF highly unlikely only where class Ic was correctly indicated, in the absence of underlying heart disease: Our note: that reassurance does not cover IART in CHD.
QRS widening >25% from baseline: reduce or stop (EHRA/AEPC 2013 Table 3; Ciriello 2024). Not advised at baseline QRS >120 ms Adult (EHRA 2025); the pediatric table lists QRS over 120 ms and QTc over 500 ms as well (Breinig 2026 Table 2). Class IA can also give paradoxical 1:1 conduction, and torsades-related syncope in up to 20% of children (EHRA/AEPC 2013) consensus
Reported: class Ic with propranolol, sotalol or amiodarone (Ciriello 2024) review
Reviews; the management they describe rests on case series and expert consensus. Consult poison control (Geanacopoulos 2024; Oeffl 2023) review
Airway, breathing, circulation; continuous monitoring and serial ECGs; charcoal only within the first hours with a safe abdomen; ECMO if refractory (Geanacopoulos 2024 Table 2)
Sodium bicarbonate 1 mEq/kg over 1–2 min, repeat until QRS <100 ms (flecainide) (Geanacopoulos 2024). Lipid emulsion 20% 1–1.5 mL/kg over 1 min, then 0.25–0.5 mL/kg/min; calcium gluconate 10% 0.5 mL/kg over 30 min (Oeffl 2023)
Fluids, atropine if symptomatic bradycardia, IV calcium, high-dose insulin 0.5–1.0 U/kg then infusion with dextrose; lipid emulsion if refractory (Geanacopoulos 2024)
Digoxin-specific Fab. Approximate dose: serum digoxin (nmol/L) × weight (kg) × 0.3. The source does not state the unit of the result; check the product label before giving it (Oeffl 2023)
Do not give calcium with suspected toxicity or low cardiac output (Breinig 2026 Table 2) guideline table, ungraded
Magnesium; correct electrolytes. Hemodialysis lowers sotalol levels (Geanacopoulos 2024)
Guideline: a society clinical guideline. FDA label: a regulatory document; most say pediatric safety is not established. Guideline table, ungraded: Breinig 2026 Table 2, a summary of the main antiarrhythmic drugs in a guideline on non-post-operative SVT in PICU; the table carries no grade. Consensus: EHRA/AEPC 2013, a pediatric statement with class and level, and EHRA 2025, an adult document whose Table 18 cites it. Society review: Leoni 2023, from the pediatric area of an Italian arrhythmia society. Expert analysis: an expert commentary on a society website, with no class or level of evidence; not a guideline. Review: a narrative review, which gathers doses from elsewhere and is not a guideline. Case report: one patient’s course, as its authors report it. Small study: a single study of a few patients, without a control group. Abstract: only the authors’ abstract was read. Adult values are labelled Adult.
Classes and targets follow EHRA 2025 Table 1, a simplified form of the 2018 Oxford classification (Lei 2018). Lei 2018 was read for its Table 1 and the passages named below, with its 2019 correction, which corrects one supplementary table row on class IIIb openers, no drug here. Lei 2025 could be read only as an abstract, listed below; it is not in PubMed Central. Mechanism statements come from EHRA 2025 and JCS/JHRS 2020, except magnesium’s, from Lei 2018. In the ECG column, PP ↑ is a slower sinus rate (JCS/JHRS 2020 Table 6 prints sinus rate) and QT uses JT where only JT is printed. n/s means not stated in a source read. By column: target, EHRA 2025 Table 1 (magnesium, Lei 2018); ECG, JCS/JHRS 2020 Tables 5 and 6 and FDA labels; acts at, EHRA 2025 drug sections and FDA labels; use cases, EHRA 2025 Tables 3 and 4 and text, with pediatric guidelines and reviews as cited in each panel; side effects and proarrhythmia, EHRA 2025 Tables 12 and 10, adult figures, and FDA labels. Doses sit closed in each panel, with each dose’s maximum and any disagreement beside it. Contraindications, warnings and monitoring stay open.
Doses and classes marked AHA/AAP 2025 were read in the sections named below, Figures 2 and 7 as images. The superseded AHA 2020 figures are no longer used.
Classes of recommendation are shown I, IIa, IIb, III for every source, as across HeartCalc; ACC/AHA 2023 and AHA/AAP 2025 print them 1, 2a, 2b, 3, and levels are kept as printed. Drug class is the modified Vaughan Williams scheme of EHRA 2025 Table 1. Geanacopoulos 2024 lists adenosine as class V. IART is the term in Przybylski 2023, Chang 2010 and Geanacopoulos 2024; EHRA 2025 writes atrial flutter or macro re-entrant atrial tachycardia. 1 mcg = 1 µg; sources print either. Our arithmetic is marked as ours. Read first carries each label’s contraindications and the Breinig 2026 Table 2 column, headed “Contraindications/safety/TDM”; hypersensitivity to the drug itself is on every label and is not repeated. Sotalol comparison used typical height and weight and the Mosteller body surface area.